exercise ; cardiovascular system








HF
complications
reporting ; cell ; Anand
doxorubicin
doctors ; blood transfusions
FM

heart failure
dXA


hz
exercise ; cardiovascular health
Renal artery stenosis

surgery ; heart transplant
mortality
molecular mechanism
tertiary referral centre

HF



mortality
breathing ; heart beat
environment

heart failure ; Latin America


Heart rate

doctors
heart failure
northwest united states


surgery
heart failure


Heart failure

clin

trans

CHF
autonomic balance
competitive

HFpEF
functional capacity

dodson

LV fibrosis

Jehovah ; witness ; anemia
medical conditions
heart failure
cardiac transplantation
correlated ; co
HF
cognitive function
Heart failure ; cognitive impairment
HF ;HF
follow-up
cardiology
exercise
Heart rate ; cardiac
remote ischemic conditioning ; heart failure
air pollution ; heart failure




policy
compliance

taxonomy
CHF
Heart failure ; uk

cardiovascular disease
HF

Heart failure
hemostasis

Caspase-3 gene expression ; heart failure
diuretic ; heart failure
right heart failure ; pulmonary hypertension
Heart failure ; bisphosphonates
functional capacity
etiology ; ms
hypertension
HF
Heart rate ; arterial pressure

Chronic HF
Cardiac amyloidosis
Robot-assisted training ; heart failure

internal reliability ; cronbach
HFpEF
ejection fraction ; bNP
Pigs ; antiarrhythmic medication
beta blockade
CHF ; intubated
circulatory arrest
functional capacity

collected ; systolic dysfunction


exercise ; heart failure
implanted monitoring devices

conditions
hz ; ea ; afterload burden
strokes

RAS ; atherosclerosis
frailty ; heart failure
microRNAs ; heart failure
Hazard ratios
psss ; exercise
heart failure ; ejection fraction
Cardiology ; bromodomain inhibition ; heart failure

vasopressin ; congestive heart failure
mitral stenosis ; medical ; heart failure
heart failure ; cardiovascular death
Trastuzumab-related cardiotoxicity ; breast cancer
heart failure ;HF ; therapy
mortality ; sts
pde2 ;HF
hospital
Heart failure ; public health
albumin level
VET ; aortic pressure curve
physician continuity
sst2

Cardiac symptoms
spironolactone ; systolic heart failure
eRK1/2 ; molecular scaffolds ; heart pathology
functional ms ; MR
Epidemiology ; chronic heart failure ; bisoprolol
Heart failure ; hz ; society


Tolvaptan ; vasopressin ; receptor antagonist
costs ; expenditures
metric ; readmission metrics
readmission metric
enrolled
follow-up


black
CHF
stable ;HF
residual confounding


baseline ; HRQol
ejection fraction outcomes
biomarkers ; chronic heart failure
hz ; cardiovascular
cardiac ; inflammatory biomarkers
mortality
heart failure
pharmacological ; acute heart failure
baseline ; heart failure
off-pump ; sternal sparing ; HeartMate II exchange
dialysis ; device implantation
Coronary angiography
Hemodynamic phenotype
ms ; surgery ; echocardiography
exercise

heart failure
nordic walking ; heart failure
Psychometric testing ; self-care of Heart Failure index
multiorgan failure ; sepsis
kidney injury
VO2max

Seattle ; Heart Failure model
healthcare
heart failure



cardiac


hz

japon
biomarkers
AIN ; tug test
ESRD
Heart failure ; left ventricular ejection fraction
AIN oUTCOME
systolic HF
outcome measures
lVAD implantation
postsystolic function
hemodynamics
pathophysiological
aac ; cardiac hypertrophy
aa ; esc
physical ; heart failure
keletal muscle abnormalities ; exercise capacity ; circulation
Readmission ; hospital ; heart failure
lead ; hypertension ; kidney failure
chronic kidney disease ;CKd
income ; expenditure ; health
change
HR variability ; cardiac death
circulation
blood pressure
significant


north assembly
cPGs
ms ; surgery

acute heart failure
heart failure
stand-alone diagnostic devices ; hz
heart failure
HF
endothelial function
Race ; spironolactone ; heart failure
heart failure ; cardiac rehabilitation
rate-control
exercise
anemia ; heart disease

Myocardial infarction ; elicited ; Wistar rats
treatment algorithms ; post- lVAD AI
AI
sinus rhythm ; af
public reporting

telehealth ; medicare
filling pressures
significant
hz ; chromatin hyperacetylation

acute heart failure

ms ; surgery
grs ; cv
deficit index

follow-up
mortality

QRs

CHF ; unilateral renal DNx ; cardiac autonomic balance
ral regurgitation ; hz ; surgery
renin-angiotensin-aldosterone system inhibitors ; heart failure
anaerobic threshold ; heart failure
surgical ; ms
af ; echocardiographic examination
nurses
economic savings ; accounting ; cost
PVf ; recovery ; pb

heart lesions
significant ; ms ; hz ; ms
ICU ; mortality
bioinformatic ; heart failure
cardiovascular events
diuretic ;HF
CAD ; systolic HF
heart disease
sst2 ; BB therapy
Heart block ; induced ; pulmonary artery snared ; BiVP
compliance
ct
beta-blockers
CHF
RM

Cardiac function ; pressure-volume conductance catheter system
evidence ; cardiomyopathy
folded protein response ; regulates ; cardiac sodium current ; systolic ; heart failure
hypoalbuminemia ; heart failure
hypertensive LV dysfunction ; ms
etiologies
angiotensin receptor ; neprilysin inhibitor ; heart failure
western blot ; immunohistochemistry ; electron microscopy
diastolic dysfunction ; peripheral artery disease
cardiomyopathy ; mortality
hff
heart transplant ; ect
proteome ; HDl particles
HF
southeastern Minnesota ; hf
bundle branch block ; electrical activation sequence
hHF ; dp-4 inhibitors ; drugs
TAC
Cardiac cachexia ; body composition
cardiac remodelling
complications ; dialysis
neurological ; cardiovascular
coronary disease ; heart failure
fm ; FM ; stable body weight ; CC
heart failure
exercise training ; endothelial function
ms ; surgery ; mva
exercise ; exercise
heart rate
cRF
DASh ; diet scores
rehospitalization
nitroxyl ; hno ; heart failure
Cardiac-resynchronization therapy ; heart failure
odds ratios ; accounting
lVET ; follow-up measurement
blacks ; VO2 ; baseline
physician ; death ; urgent readmission ; discharge ; heart failure
hf ; hfpEF
hospital-to-Home ; hospital ; readmission reduction ; congestive heart failure
heart failure
diabetes ; edoc-cFUs

transplants
aerobic exercise

trastuzumab-related CHF

Peak VO2
pharmaceutically
financials
Coronary artery disease ;cad ; systolic heart failure ; hz
hypoalbuminemia ; lVAD ; surgery
psoriasis ; atherosclerosis ; cardiovascular events ; Rotterdam
mortality ;HF ; hospital admissions ; transplant ; ventricular assist device
Heart failure ; rheumatoid arthritis ; tNF antagonist
holosystolic murmur ; heart
stroke ; heart failure
HF ; haemodynamic ; neuronal stressors
biological ; mortality
right ventricular function ; body composition ; heart failure
Fat ; cachexia ; right ventricle ; heart failure ; complicity
atrial fibrillation ; af ; heart failure
ect ; advanced heart failure therapy
heart transplantation ; left ventricular assist device
exercise intolerance ; chronic heart failure
avd ; VVD ; free wall
connected ; heart failure
baseline ; eCGs ; electrocardiographers
left ventricular assist device ; right ventricular
incidence ; ESRD ; outpatients ; hz
wilcoxon ; signed-rank tests
subclinical atherosclerosis
Renal artery stenosis ;RAS ; peripheral arterial disease
baseline ; ect ; cardiac transplant recipients
eplerenone
recovery
extubated ; blood loss ; transfusion
technique ; malfunctioning HeartMate II lVADs
Heart failure ;HF ; cardiovascular
veg inhibition ; cardiac function
β-blocker ;BB ; sst2
miRNAs ; cardiac pathogenesis
PET ; exercise ; CHF
heart failure ; ejection fraction
heart failure
Pediatric heart failure ;HF
expression ; regulatory ;RI ; hz

bromodomain proteins
mortality
heart failure care
bt ; dt ; implantation

hypotension
biomarkers ;HF
HF
ST2 ; plasma
condition ; economic
medications ; heart failure
mortality rate
coronary heart disease ; stroke ; heart failure
significant ; mlf
septal defects
mortality ; iCD-HF
renal denervation ; autonomic balance ; rabbits ; chronic heart failure

trastuzumab
germline DNA
Heart failure ; disease ; medical
circulating plasma ; rabbits
HF
blood work ; medication
np assessment ; ED
Cardiac hypertrophy ; energy metabolism
lVAD implantation
HDl-bound malondialdehyde
renal dysfunction ; post-transplant morbidity
CAD ; CAD


hospital discharge

anemia ; heart disease
right atrial myxoma ; pulmonary embolism ; right heart failure
nafat ; mir-25 ; transcription factor ; hand2 ; heart failure
ejection fraction
Orthotopic heart transplantation ; oj ; heart failure
myxomas ; pulmonary arterial vasculature
readmissions ; follow-up ; heart failure ; readmission quality
lVAS ; transplantation
Cardiac overexpression ; Mammalian ; mena ; heart failure
cps ; functional capacity ; VO2
pump failure ; driveline ; injury ; pump replacement
canine model ; chronic heart failure ; tachycardia
Nicorandil ; doxorubicin
eh ; hfpEF
east ; rhythm control ; cardiovascular complications ; af
radiological ; hz
diuretics ; heart failure ;HF
evidence-based therapies ; fes
heart failure
Framingham Heart study ; hz
HF
acr ; CMS
activated Caspase ; paced myocardium
heart failure ; health
hf ; saxagliptin ; sitagliptin
Heart ; heart failure ; arrhythmias
ischemic ; abdominal ; MT
ed ; intubations ; congestive heart failure
medline ;EMBAse ; cim
evidence ; acp
exercise ; coronary artery disease ;CAD

change
ed ; CHF

Medicare ; post-acute care transfer policy
mortality

degs ; osprey

world health organization ; hz
deficit index
implantation ; ct
necdotal evidence
iron
remote monitoring ; hospital discharge ; heart failure
LV ; filling pressure ; stable systolic HF
Soluble ST2 ; heart failure ; functional capacity
baseline ; echo cards ; reverse remodeling
Titin hypophosphorylation ; myocardial
right ventricular contractile reserve ; pulmonary hypertension
bottleneck stent model ; chronic myocardial ischemia ; heart failure ; pigs
QT intervals ; SD ; QT intervals ; sdp
Gastrointestinal bleeding ; ventricular assist devices ; cardiac nurse
benefit ; β-blocker uptitration ; hfpEF
compliance ; exercise
pump exchanges ; pump ; pump thrombosis ; hemolysis events
cardiac resynchronization therapy ; heart failure
noc ; admission ; discharge
HRQol ; exercise ; baseline
inpatient records ;HF
skeletal muscle mass ; VO2
cardiac catheterization ; extubated
psychosocial factors ; exercise training ; heart failure ; hz
medical ; heart failure ; Canadian Cardiovascular society
active
report model ; aRIC HF
atrial fibrillation ; pacemaker
mortality predictors ; iCD-HF
cardiovascular
catheter ablation ; sinus rhythm
body mass index ; cRF ; treadmill exercise testing
myocardial tissue ; pka
paediatric cardiac transplants
ventricular-arterial coupling ; SV
diastolic failure ; cardiomyopathic ; flow
autonomic nervous system activity ; qTV
pneumonia ; conditions
technique ; significant ; myocardial fibrosis


exercise ; diet
white
thics Rounds

biomarkers ; neurohormonal stimulation ; inflammation ; endothelial dysfunction
Heart Failure ; Pathophysiology ; medical
anemia ; heart disease ; american college of Physicians
heart rate reduction ; ivabradine unloads ; left ventricle ; heart failure
renal disease ; systolic heart failure
rvpo ; BiVP ; RS synchrony
renal DNx ; cardiac autonomic balance ; CHF ; sympathetic tone
resistin ; cardiotoxicity
acute autonomic nervous system modulation ; qTV ; hz
Heart rate ; aortic blood flow ; doxorubicin

myocardial pde2 ; expression ; activity ; hz
BAT ; sympathetic outflow ; parasympathetic activity
echocardiographic predictors ; reverse remodeling ; cardiac resynchronization therapy
cardiovascular death ; hz ; exercise training ; btes
training ; heart failure ; lipoprotein
Neurohormonal abnormalities ; pathophysiology ; congestive heart failure ; chf
parasympathetic neurotransmission ; acetylcholinesterase inhibition
LVf ; long-term mortality
DASh ; diet scores ; mortality ; heart failure ; women ; health Initiative
Jehovah ; witness ; disease ; anemia
miRNAs ; heart failure
dobutamine ; furosemide ; oxygen flow
health Buddy program ; ed
tension inhibition ; rad ; congestive heart failure
cps ; diabetes
breast cancer ; cardiotoxicity
pulmonary artery ; pulmonary artery
mri scanner ; baseline ; heart failure

congestive heart failure ; chf
muscle-wasting syndrome ; heart failure ; Fontan

ed ; CHF ; intubation rates
bisoprolol ; mortality
health Buddy program ; telehealth system
Medicare
conditions ; hospital discharge
therapeutic ; heart failure
psss ; exercise
defense mechanism ; cardiac stress ; β-ar drive
chromatin subproteome ; heart
correlated ; septal wall ; avd ; free wall ; VVD
echocardiography ; baseline
transplantation ; circulatory assist device
biventricular pacing ; left heart ; twist ; right heart failure
etiologic ; acute rv failure ; left ventricular dysfunction
cps ; functional capacity ; heart failure ;HF
inhibition of protein kinase ; guanylate cyclase ; contractile
circulating progenitor cells ; heart failure
doppler echocardiography ; pulmonary hypertension
systolic ; diastolic mitral leaflet ; organic lesion
mortality ;HF
significant ; hz
t test ; cis
radiological ;HF
mortality ; bNP ; mortality
aCS ; operation
right ventricle ;rv ; cardiac function ; medical
costs ; heart failure ;HF
RV dysfunction ; weight loss ; body mass ratio
HR ; beta blockers ; exercise capacity ; hf
cardiopulmonary exercise ; heart failure
Canada
activity ; myocardial washout
myocardial diastolic dysfunction
outcome ; death ; heart failure
baseline ; ST2 ; interquartile range
black race
outcome change scores ; heart failure
diagnostic
chemotherapy-induced heart failure ; breast cancer
exercise
pressure ulcers
hf ; ms ; significant ; mva
pd ; refractory ; end-stage congestive heart failure ; chf

beta blockers ; mortality ; heart failure
transcatheter ; surgery
monitoring board
complication
chelation regimens ; heart iron
consultation ; abdominal
time up & go test ; chronic organ failure
NYha ; functional assessment
follow-up
mortality
ventricular ejection time ; heart failure ; precapillary pulmonary hypertension
chirurgical ; aortic valve insufficiency ; left ventricular assist device ; implantation
ejection fraction ; cardiac resynchronization therapy ; heart failure
outcome ; functional capacity ; mwt
hff ; sodium restriction ; ventricular ; vascular
magnetically Levitated left ventricular Assist system ; hz
CHF ; explants ; sham explants
chronic heart failure ; ghf ; sympathetic tone ; autonomic imbalance
Heart failure ; mortality ; society ; cardiovascular diseases
extracorporeal membrane oxygenation ; bridge to recovery ; right heart failure
echocardiographic ; invasive hemodynamic
cardiac catheterization ; thrombotic obstruction ; right coronary artery
california ; health ; discharge
Font failure ; systolic ventricular function ; significant liver disease
HF
cardiomyopathy
mechanistic ; electromechanical delay ; dyssynchronous heart failure
trastuzumab ; cardiac

economic ; af ; heart failure ; Québec ; Canada
cardiac Mena deletion ; cardiac dysfunction ; hypertrophy
bundle-branch block ;LBb ;LBb
protein levels ; western blot ; DNA fragmentation ; tunel method
herbal medicine ; dilated cardiomyopathy ; heart failure
implantable ; cardioverter-defibrillator deactivation
cardiac filling pressures
right atrium mass ; tricuspid valve ; stenotic physiology
cutoff level
heart failure ; protein kinase ; expression
HF
Seattle ; Heart Failure
dopamine ; nesiritide strategy
nitrite
neurological ; cardiovascular ; event-free rate
cardiovascular events ; psoriasis
cp
flow-mediated dilatation
aHF
systolic function
BETs ;TAC ; hz
health
cardiac nurses
consultations
transfusion thresholds ; mortality
Czech republic
MAD-ct


heart failure
western blots ; monoclonal antibodies ; ser83 ; phosphorylation ; hz
preoperative serum albumin levels ; left ventricular assist device implantation
New York ; Heart association
ms ; ring annuloplasty ; ischemic MR ; LV
change ; Paco2 ; cerebral blood flow ; carotid bodies
vasopressin receptor antagonist ; tolvaptan ; heart failure
pathophysiology ;HF ; medical
ed ; New Jersey ; New York
psoriasis ; smoked ; diastolic blood pressure ; body mass index
exercise intolerance ; heart failure ; exercise
echocardiography ; baseline ; implantation
ventricular assist device ; extracorporeal membrane oxygenation ; renal function ; heart failure
cox models ; ST2
tm ; sts
HRQol
circulation ; hz
energy metabolism ; heart failure ; hypertrophied heart
ms ; dynamic ; ms
PAD ; ankle-brachial index
HR ; ivabradine ;TAC ; ea
baseline ; mechanical cardiac ; renal function
ecmo ;VAD
mortality ; morbidity ; cancers ; budget
heart disease ; rate control
inotropic effect ; beta blockers ; heart failure
interleukin receptor ; ST2 ; beta-blocker therapy ; chronic heart failure
heart failure ; systolic heart failure
baseline ; rhythm-control ; rate-control
hemoglobin levels
functional ms ; medical ; treatment
hf ; epidemiology ; health service ; hf
Heart failure ; hz
heart failure ;HF
lVAD ; AI ; heart failure
evidence ; anemia ; heart disease
ventricular dilatation
ventricular assist devices
implanted
renal dysfunction ; mechanical cardiac
HF
computing readmissions
exploratory factor ; cfa
pb ;HF ; central pattern generator

serum factors ; coagulability
iCD

bNP ; NT-probNP ; biomarkers ; heart failure
Cardiorespiratory fitness ; body mass index ; heart failure mortality ; cooperation center longitudinal study
pro-adrenomedullin ;MR-proadm ; fm

Heart failure ;HF ; sympathetic activity ; parasympathetic control ; heart
mortality ; implantable cardiac defibrillator
ATP ; ROS ; mitochondrial respiration ; contractile function
physical ; cardiovascular ; diabetes mellitus ; hypertension ; hyperlipidaemia
systolic HF ; etiology ; coronary angiography
rial fibrillation ; congestive heart failure ; cost ; rhythm-control ; rate-control
ejection fraction ;EF ; myocardial perfusion
circulating ; natriuretic peptides ; plasma ; heart failure
heart failure ;HF ; left ventricular ejection fraction ; hpEF
heart failure ; implantation ; ventricular assist device
hz ; cardiac murmurs ; blood pressure
receptors ; adenylyl cyclase ; differential g-protein coupling
hz ; vt ; beat-to-beat QT
biventricular dysfunction ; outcome ; HeartMate II
tug test ; COPd ; CHF ; cRF
pressure-overload-induced heart failure
mandate ; accountable
medical ; hemodynamically ; cp
isoproterenol ; cXL-1020 ; myocytes ; hearts
cardiac angiogenesis ; coronary perfusion ; cardiac fibrosis
heart failure ; ventricular tachycardia
Pyridostigmine ; myocyte diameter ; collagen density ; left ventricle
exercise intolerance ; chronic hff
energy substrate metabolism ; hearts ; aac
evidence ; schfi
rule ; CAD ; CAD
diabetes mellitus ; cardiovascular disease ; baseline
cvd ; psoriasis
exercise ; haemodynamic ; pulmonary
diagnostic ; rule
Rotterdam ; psoriasis ; cardiovascular outcomes
HR ; tnf ; nbDMARD
acs ; MT ;VAD
general hospital ; cardiac specialty hospital ; south dakota
medical records
ecmo ; egFR ; egf
administration ; trastuzumab-related CHF
hz



cardiac death
cachexia ; rv ; body composition
hospital mortality
hospital length ; rehospitalization
cognitive impairment
sonographic ; histological ; functional abnormalities
nauretic peptide levels ; biomarkers
anticoagulants ; antiplatelet drugs ; heart failure ; atrial fibrillation
Spironolactone ; hyperkalemia ; kidney injury
bNP levels ;PAD ; bNP ; hz
sympathetic ; parasympathetic activity ; hz
eh ; systolic blood pressure ; renal impairment ; hypertension
exercise ; hz
hz ; transition ; LV hypertrophy ; hz
left ventricular longitudinal systolic strain ; cardiovascular events ; atrial fibrillation
heart transplantations ;LV ; implantations ; heart failure admissions
chronic myocardial ischemia ; heart failure
hfpEF
mechanical cardiac ; renal function ; heart failure
medical revascularization ; catheter-based revascularization
baseline ; exercise ; training
Morpholino-based knockdown ; nucleolin ; expression
derive ; rule ; CAD ; systolic ; hz
pump-exchange technique ; sternotomy ; cardiopulmonary bypass
ms ; medical ; ms ; dynamic ; medical
parasympathetic function ;HF
medical ;HF ;HF ; ms ; mva
jugular venous pressure ; peripheral oedema
Heart failure ;HF ; condition
functional mitral stenosis ; ring annuloplasty ; ischemic mitral regurgitation
circulation ; svr index ; cardiac index
isolated lVAD
mineralocorticoid receptor antagonists
hereditary ; congenital abnormalities ; heart ; nontraumatic death
circulation ; skeletal muscle mass ; metabolic abnormalities
HeartMate II lVAD

health insurance ; health system ; u.s. Food and Drug administration
cutoff value ; NT-probNP testing ; ed ; acute heart failure
blacks ; hypertension ; diabetes ; etiology ; socioeconomic ; whites
albumin levels ; lVAD
cytoscape ; daVID
cardiovascular conditions ; hz

emd
right heart circulation ; right heart failure
Raf-MEK1/2-erk1/2
hz
bisphosphonate ; heart failure
costs
sustainability

Xanthine oxidase inhibition ; ventricular systolic ; diastolic function ; cardiac
diagnose ; heart failure ; preserved ejection fraction ; doppler echocardiography
heart failure ;HF ; Heart Failure adherence ; tension trial ;HAR
HF ; preserved ejection fraction ;HFpEF ; hypertension
NYha
Myocardial infarction ; left anterior descending coronary artery occlusion
hfpEF ; breathlessness ; fatigue
immunodetection ; NT-probNP ; antibodies
nordic walking ; cardiac rehabilitation ; functional capacity ; heart failure
parasympathetic tone ; pyridostigmine ; ventricular dysfunction ; heart failure
β-Blockade ; cardiac angiogenesis ; heart failure ; veGF
myocardial ischemic events ; cardiac resynchronization therapy
report ; aortic valve surgery ; post- lVAD
unloading ; heart ; HR reduction ; systolic heart failure
spironolactone ; systolic heart failure
Heart failure ; medicine ; atheromatous coronary disease
Heart failure ; hz ; Latin America ; lam ; health service ; hz
rehospitalization ; medicare
hz ; ct ;hazard ratio
palliative
diagnostic test ; hfpEF ; medical ; physical
oxidative stress ; GTPase Rac1 ; activity ; hearts
circulating mediator of insulin resistance ; monocytes ; inflammatory stimuli
cardiovascular death ; cardiac transplant ; death
medications ; heart failure ; NCDR PINnaCLE
beta-blockers ; cardiac sympathetic activity ; hemostasis ; heart failure
readmission rate
transformed
Intravenous iron ; heart failure ; iron deficiency
art failure ; Emergency department ; ed ; ed
conditions ; heart failure
ischemic ; ischemic heart failure
psoriasis ;UV
RV dysfunction ; weight loss ; body composition ; hz

significant
diastolic dysfunction ; hff
β-adrenergic receptor blockade ; mortality ; heart failure ;HF
right ventricle overload leads ; stroke volume ; ventricular ejection time ;VET
NT-probNP ;HF ; immunoprecipitation ; mass spectrometric
chromatin-associated proteins ; chromatin structure ; DNA ; gene expression profile
pd ; complications ;HF
pulmonary hypertension ; heart failure
robot-assisted gait therapy ; Lokomat ; heart failure
catheter ablation ; antiarrhythmic drugs ; rhythm control therapy
HDl function ; HDl function
Cardiac failure ; diabetes ; molecular mechanism ; diabetes ; heart failure
exercise ; hemodynamic
lVET ; death ;ICU
congestive heart failure
abm ; implantable ; cardioverter-defibrillator deactivation
mitochondrial ; sarcomeric microstructure
heart failure ; ejection fraction
gut ; inflammation ; heart failure ; heart failure
pp ; acr ; CMS
mortality ;LCx ;LAD
CHF ; ed ; intubated
CHF ; activated neurohormonal systems
zSF1 ; heart failure ; ejection fraction
follow-up ; discharge ; readmission ; heart failure
heart magnetic resonance imaging ; compliance ; heart disease ; thalassaemia
arterial tonometry ; lVET ; precapillary PH ; heart failure
cross-talk ; heart ; adipose tissue ; cachectic heart failure ; body composition
mutant mice ; hand ; heart muscle cells ; pathological hypertrophy
transoesophageal echocardiography ; thrombosis
heart rate ; renal function ; spironolactone
dialysis ; echocardiographic outcomes
evidence ; microRNAs ;miRNAs ; heart failure
PARADIGm-HF ; chronic heart failure ; Chronic heart failure ; cardiology
ambulatory HF ; ventricular ejection fraction
New Zealand ; white rabbits ; renal DNx ; CHF
QT variability ; qt ; qt ; cardiac death
Beta-blocker ; bpm
mri ; tidal respiration ; myocardial ; swine ; heart failure
cardiovascular disease ; baseline
advantage ; poc ; technology
psoriasis ; cardiovascular disease ; cvd
AMI ; mortality rates
readmissions

Rhythm control therapy ; side effects
likelihood ratio
costs
cardiac dysfunction ; subcellular ; metoprolol ; heart failure ; myocardial infarction
diastolic dysfunction ; filling pressures ; doppler echocardiography
Cardiac magnetic resonance ; heart failure ; ejection fraction
myocardial collagen ; titin isoforms ; phosphorylation
RAS-blocker uptitration ; hf ; hfpEF
Hemoglobin ; exercise ; heart failure
systems proteomics ; cardiac chromatin ; nucleolin ; regulator of growth ; cellular plasticity ; cardiomyocytes
Plasma samples ; collected ; hz
pde2-overexpressing cardiomyocytes
heart failure ; ccnka sNP
GDm ; GDm ; BAT
baseline
transduction pathways ; proteins
alendronate ; alendronate ; heart failure
cardiovascular disease ; dRS
index admission ; index admission

beta-blocker therapy
heart failure ; bisphosphonates
heart failure ; hz
miRNAs ; cardiac remodeling ; heart failure
medical ; hf
diastolic dysfunction ; mortality
alphaLISa ; immunoassays
Fontan ;SAF ; catheterization
death ; biological phenotype
sinus rhythm ; antiplatelet agents ; anticoagulants
implantable ; cardioverter-defibrillator deactivation
heart failure ; left ventricular ;LV ; ejection fraction
cardiotoxicity ; doxorubicin ; anti-neoplastic agent ; cancers
acs ; bridged to transplant ; mdp ;VAD
natriuretic peptides

cardiac angiogenesis ; therapy ; cardiac function
hf ; rheumatoid arthritis ;RA
expression ; Bax ; bcl-2 proteins
financials ; conditions
regulation of feeding ; nutritional ; anti-inflammatory effects ; CHF
drugs ;HF ; ejection fraction ; hf
hyperkalemia ; kidney ; spironolactone
renal denervation ; dnx ; CHF
MT ;VAD ; acs ; consultations
refractory congestive heart failure ; peritoneal dialysis
Mammalian enabled ; mena ; regulator ; cytoskeletal actin dynamics ; heart failure ; hz
heart failure ; elevated left atrial pressure ; admission
Heart failure ; preserved ejection fraction ; hff ; cardiovascular reserve
diastolic dysfunction ; combination ; figure ; mechanism ; hff
follow-up ; physician ; heart failure
ambulatory iCD ; mortality
arni inhibitors ;angiotensin-receptor neprilysin inhibitors
Gastrointestinal bleeding ; ventricular assist devices
nicorandil ; cytotoxic effect ; doxorubicin ; ehrlich carcinoma
myxomas ; cardiac benign tumors
fes ; ejection fraction ; hf
diagnostic ; bNP ; NT-probNP ; coronary artery disease ;CAD
exercise
NT-probNP
ect
aerobic capacity ; left-hand grip strength

myocardial loss ; irs1 ; irs2 ; heart failure ; p38alpha maPK ; insulin resistance
heart failure ; hypertensive heart disease ; angiotensin II infusion ; nephrectomy ; salt loading
functional mitral stenosis ; ms ; ring annuloplasty ; ischemic mitral regurgitation ;MR
ICU ; admission ; precapillary PH ; heart failure
heart failure-related hospitalization ; left ventricular ejection fraction
Heart failure ; preserved ejection fraction ; hfpEF ; cardiovascular morbidity
doppler imaging ; left ventricular filling pressure ; systolic heart failure
zSF1 ; obese ; zSF1
heart failure ; preserved ejection fraction ; hff
Kansas City ; Cardiomyopathy Questionnaire ; heart failure ; ejection fraction
myocardial pde2 ; intracellular antiadrenergic ;HF
spironolactone
HF
heart failure ;HF ; death ; ct-d
pharmacologic
mechanical dyssynchrony ; QRs ; ct
coronary occlusion ; significant collateral growth ; stent occlusion
carotid ; intima-media thickness ; psoriasis
transfusions ; heart disease
combination ; exercise ; diet ; peak VO2 ; joint effect
PVf ; pb ; pb
chronic heart failure ; Hungary
rv dysfunction ; cardiac cachexia
remote monitoring ;RM ; heart failure
ecg ; ct
sst2 ; cardiovascular
breast cancer ; trastuzumb-related CHF
hz ; emd ; dyssynchronous failing heart
acute heart failure ; HF ; heart failure ;HF
angiogenesis ; post-myocardial infarction heart ; heart failure
aldosterone antagonist ; heart failure
surgery ; medical ;HF ; hypertension ; vasodilators ; diuretics
Genetic susceptibility ; anthracycline-related congestive heart failure ; haematopoietic cell transplantation
HR ; beta-blocker therapy
pde2 ; hearts
psoriasis ; disease ; atherosclerosis ; cardiovascular ; psoriasis
heart disease
heart failure
egf ; diuretics ; hypertension ; ESRD
trastuzumab ; CHF ; nontrastuzumab
oeso-cFUs ; mortality
pn ; ed ; outpatient ; acute heart failure
heart failure ; ejection fraction ; myocardial infarction
lVAS
black race ;HF ; cardiovascular mortality
exercise ; health benefits ; cardiac disease ; heart failure
hff
hz cPGs
HF ; risk factors ;HF mortality
HDl function ; CHF ; vascular
coronary artery disease ; systolic heart failure ; etiology
implants ; transseptal catheterisation ; transoesophageal echocardiographic
ea ; arterial compliance ;TAC ; end-systolic elastance ; ees ; baseline
cardiovascular ; HeartMate II lVAD ; centriMag rVAD ; mortality ; discharge
Renal dysfunction ; mortality ; myocardial infarction ; coronary artery bypass grafting ; cab
cardiovascular risk factors ; diabetes mellitus ; atrial fibrillation ; coronary artery disease ; hfpEF
baseline ; isoprenaline infusion ; SDQT ; hNorm ;HF
renal dysfunction ; mortality ; cardiovascular events ; primary isolated caBG
Pyridostigmine ; vascular endothelial growth factor ; left ventricle ; myocardial angiogenesis
egf ;VAD
CHF ; international Classification of Diseases
rv dysfunction ; body mass index ; fat mass index ; cachexia
baseline ; cf ;HF ; mortality risk ; HF
Robot-assisted gait therapy ; Lokomat ; heart failure
cardiac
idiopathic dilated cardiomyopathy cohort
dopamine ; nesiritide
medline ;EMBAse

HF ;HF
baseline ; ea ;TAC
telehealth technology ; health outcomes ; Medicare
ERC ; muscle function
biomedical
myocardium ; expression ; pka ; downstream
atrial fibrillation ; carvedilol ; metoprolol
ground theory ; collect ; heart failure ; implantable ; cardioverter-defibrillator
ms ; valve plasty ; MR ; LV ; disease
HeartMate II ; biventricular ; HeartMate II implantation
end stage heart failure ; Heart failure ; public ; health ; europe ; northamerica
conditions
heart failure ; mechanical ; Cardiology-cardiovascular surgery Consensus report ; Heart failure
elastic n2bus ; PEvk
self-Care of Heart Failure index ; schf ; psychometric profile
proteomics ; detergent
HeartMate ; left ventricular assist system ; lVAS ; heart failure
Nicorandil ; mitochondrial dysfunction ; doxorubicin-induced heart failure ; mechanism of cardioprotection
pharmacologic ;HF ; chronic HF
arterial elastance ; pulsatile afterload ; heart
cXL-1020 ; inactive ; cXL-1051
tNF antagonists ; hf ; hospital admissions ; nbDMARDs ; RA
ejection fraction
grs ; cv
exercise ; diet ; exercise
mortality
nurses
evidence
hz ; drug treatment ; PAf ; biosynthetic enzymes
epidemiology ; myocardial infarction ; heart failure ;HF
cardiac magnetic resonance imaging ; invasive hemodynamic assessments ; baseline
Heart rate reduction ; exercise ; heart failure ; ejection fraction ; beta-blocker
RAS ; hypertension ; nephropathy ; congestive heart failure
admission ; serum levels ; brain natriuretic peptide ; bNP ; creatinine ; natremia
mADIt-ct ; multicenter Automatic Defibrillator implantation ; Cardiac resynchronization Therapy
baseline
isoelectric focusing ; RIα ; ser77 ; ser83 ; vivo phosphorylation
SDQT ; rr intervals ;SDr ; ncw ; heart rate
ucs ; resynchronization
Logistic regression models ; outcome ; outcome
icc occlusion ; twist ; apical rotation ; RS ; RS synchrony
readmission rate ; congestive heart failure ; united states
diuretics
readmission rate ; heart failure
significant gastrointestinal bleeding
ms ; cardiac events
egf ;VAD ; renal function
sst2 ;low-dose BB ; sst2 ; high-dose BB
CHF ; ed ; CHF ; intubated
physical ; mortality ;HF ; noncardiologist
zebrafish ; nucleolin
LV ; ejection fraction ; pcwp
incidence ; hf ; am ; mortality
acute heart failure ; Collins
cardiopulmonary exercise test ; muscular strength ; peak quadriceps force
public health ; air pollution ; cardiovascular health ; lead
ecg ; ion channelopathies ; cardiomyopathy
idiopathic dilated cardiomyopathy ; tuscany
hz ; pyridostigmine ; basal heart rate ; vagal ; sympathetic control ; heart rate
mortality ;HFpEF ;HF ; treatment
HF ;heart failure ; t2d ; diabetes ; Skm ;keletal muscle
heart failure ; hz
evidence ; molecular biomarkers ; pathophysiology ; chronic HF
carvedilol ; metoprolol ; heart failure
erythropoiesis-stimulating agents ; anemia ; heart disease
intravenous iron ; exercise ; heart failure
report ; mitral valve plasty ; mitral regurgitation
costs ; Québec ; health insurance board ; costs ; Ontario ; case costing Initiative
BET ; bromodomain-containing protein ;brd4 ; cardiac tissues
RAS ; neprilysin inhibition ; change ; chronic heart failure ; systolic dysfunction ; treatment
change ; readmission rate
heart failure ; mechanical cardiac
economic ; lVAD
multiparametric echocardiographic score ; ct
ejection fraction
af ablation
If-channel inhibition ; hemodynamic ; exercise ; heart failure ; ejection fraction
administration ; gadolinium-chelate contrast agent
Cardiac insulin-resistance ; mitochondrial energy production ; systolic heart failure ; pressure-overload hypertrophy
Medicare ; hz ; admissions ; acute care hospitals ; united states
catheter ablation ; atrial fibrillation ; heart failure ; ejection fraction
low-dose dopamine ; low-dose nesiritide ; acute heart failure ; renal dysfunction ; ROse ; acute heart failure
report ; DAPc ;dystrophin-associated protein complex ; sarcomeric ; baseline
mouse ; hh ; salt loading ; uninephrectomy ; ANG II infusion
HF ; ejection fraction ; pEF
Myocardial titin hypophosphorylation ; heart failure ; ejection fraction ; metabolic
echocardiographic predictors ; cardiac resynchronization therapy ; crt
baseline ; serum creatinine ; serum potassium
chromatin subproteomes ; heart failure ; mechanisms ; chromatin structure
Hum-retn mice ; cardiac mRNA ; inflammatory ; cell adhesion genes
anemia ; chronic heart failure ; hz
university of Connecticut ; Heart Failure center ; cardiologist ; heart failure
NT-probNP ; antibodies ; nonglycosylated
rv ; diagnostic ; intrinsic left ventricular dysfunction
pd ; weight loss ; diuretic
Chronic heart failure ; transforming growth factor ; functional
HFpEF ; kv
HeartMate II lVAD ; centriMag rVAD
exercise ; heart failure
hf ; MI ; ejection fraction ;EF
admissions ; emergency department ; ed
nbDMARD ; tnf ; baseline
trastuzumab ; cardiotoxicity ; congestive heart failure ; chf
pyridostigmine administration ; methylatropine ; propranolol ; cardiac sympathovagal balance
uPR effectors ; protein kinase ; er kinase ; calreticulin ; chop ; hz
myosin binding ; protein-c phosphorylation ; ser23/24 ; troponin I phosphorylation ; hz
echocardiographic measures ; natriuretic peptide
Phosphodiesterase-2 ; hearts ; beta-adrenergic responses ; cardiomyocytes
carvedilol ; thromboembolic events ; heart failure ; β2-receptor haplotype status
hf ; exercise ; hz ; beta-blocker therapy
baseline ; PAf ; activity ; metabolic enzymes ; heart failure
XO inhibition ; cardiomyocyte bioenergetics ; LV ; chronic acf
rcts
ESRD ; death ; ESRD ; death ; ESRD
renal dysfunction ; stroke ; myocardial infarction ; heart failure ; caBG
heart failure ;HF ; cardiopulmonary exercise test ; anaerobic threshold
heart failure ; heart failure ; cardiology
HF ; pyridostigmine ; stroke ; ejection fraction ; cardiac output ; contractility ; left ventricle
cardiac deaths ; atherosclerotic CAD
surgery ; rheumatic ; ms ; surgery ; mva
health Initiative ; hf ; contact
infarcted ; left ventricle end-diastolic pressure ; hg
rv ; pathophysiologic mechanisms ; rv dysfunction
dialysis-dependent ;HF ; ct implantation ; complications
Peak oxygen consumption ; oxygen pulse
economic ; NHs ; exercise
post-hCT CHF ; ht ; City of Hope

vena cava ; icc ; snared
doxorubicin ; serum resistin levels ; Hum-retn mice
costs
CHF

aldosterone receptor antagonists ; mortality ; systolic heart failure
scn5a ; ucp ; cardiac genes ; hz
east ; rhythm control therapy ; af ; cardiovascular complications ; af
albumin levels ; nutrition ; hepatic function ; lVAD ; implantation
right ventricular ;rv ; left ventricular assist device ; lVAD
passage ; pasp ; downward regression line shift ; pasp

lipolysis ; energy expenditure ; natriuretic peptides ;NPs ;cc
non-fatal stroke ; heart failure
hearts ; mena ; cardiac injury ; mena ; hz ; pathophysiology
biomarkers ; molecular dysfunction ; chronic HF
ST2 ; discrimination
AIN oUTCOME ; gls ; index beat method ; cv
ischemic ; ischemic heart failure ; biomarkers ; heart failure
VAD ; ecmo ;VAD ; ecmo
Ambient air pollution ; cardiovascular ; health ; acute myocardial infarction
ccq ; kaplan-meier curves ; death
RAS ; doppler ultrasonography ; tomographic angiography ; magnetic resonance angiography
testosterone therapy ; exercise rehabilitation ; heart failure ; testosterone status
pathophysiologic mechanism ; renal underperfusion ; renin- angiotensin-aldosterone pathway
AMI ; heart failure ; kidney infection ;UTI
proteomics ; pathway analysis ; pressure-overload-induced heart failure ; mitochondrial-targeted peptides
nicorandil ; cardioprotection ; apoptotic signaling pathway ; DNA fragmentation ; mitochondrial ultrastructural changes
icc ; multicenter Automatic Defibrillator implantation ; trial-Cardiac resynchronization Therapy
Olmsted County ; Minnesota ; MI ; hz
health Buddy program ; chronic obstructive pulmonary disease ; mortality ; heart failure
collected ; medical ; hz
mortal incidence ; odds ratio ;hazard ratio ; hz ;AMI ; admission ; discharge
neurohumoral blockers ;HF
left ventricular ejection fraction ; mortality ; heart failure ; Heart failure survey ; israel
vascular endothelial growth factor ;VEg ; transition ; compensatory hypertrophy ; cardiac failure
rule ; CAD ; sensitivity ; CAD
hypoalbuminemia ; postoperative mortality ; left ventricular assist device ; lVAD ; implantation
apoptosis ; pathogenesis ; heart failure

diuretic efficacy ; neurohormonal activation
uPR ; mRNA splice ; cardiac ; hz
LVEF ; LVEF
evidence ; lVAD ; transplantation ; budget
BETs ; pathological stress
ecg ; atherosclerotic CAD ; cardiac death
hf ; am ; mortality
ct-d ; significant ; defibrillator-only therapy
HR dynamics ; HR
cardiopulmonary exercise ; echocardiographic assessment ; myocardial function ; left ventricular filling ; exercise
echocardiography ; ste ; BiVP ; right ventricular pressure overload ;rvpo
atrial fibrillation ; atrial tachyarrhythmias ; ATP ; shock therapy
coronary revascularization ; hemodynamically ;ICU
obesity ; diabetes mellitus ; metabolic risk factors ; heart failure ; ejection fraction
bNP ; hz ; bNP
perk inhibition ; full-length scn5a ; kv4.3 ; mRNA ; mRNA splice
LVf ; mortality ; hz
mena ; expression ; hz ; mena ; cardiac pathophysiology
salt loading ; uninephrectomy ; ang II infusion ; cardiac function ; hz
echocardiographic ; LV ; reverse remodeling ; sensitivity
atrial fibrillation ; af ; heart failure ; hz ; stroke ; anticoagulation
hz
bottleneck stent ; myocardial infarction ; antiplatelet medication
lung ; incidence
Font failure ; circulatory derangement ; hemodynamic ; portal hypertension ; cardiac output
Trastuzumab ; CHF ; nontrastuzumab ;hazard ratio
systolic heart failure ; spironolactone
Rad variant ; congestive heart failure
functional enrichment ; regulation of programmed cell death ; degs
atrial fibrillation ; treatment ; atrial fibrillation ; stroke prevention
etiology ; comorbidities
evidence ; intestinal morphology ; absorption function ; CHF
exercise ; anaerobic metabolism ; respiratory
arni ; cardiovascular mortality ; heart failure
myocardial dd ; muscle strip ; titin hypophosphorylation
training ; peak quadriceps force
expression ; cardiac hypertrophy ; functional ; nucleolin
idiopathic dilated cardiomyopathy
readmission rates
np measurement ; POc measurement ;NPs
benefits
Kansas City ; Cardiomyopathy Questionnaire ; kv ; hz ; hzpEF
tricuspid annular plane systolic excursion ; pulmonary arterial systolic pressure ; heart failure ; index of right ventricular contractile function
biventricular ; hybrid ; HeartMate ii ; lVAD ; centriMag ; right ventricular assist device ; rad
Blood pressure ; arm cuff ; stroke volume ; ejection fraction ; end-diastolic volume ; echocardiography
fibrosis ; heart failure ; myocardial tissue ; left ventricular tissue ; histologic
snp ; renal chloride channel ; ccnka
exercise training ;HF ; exercise
contractile function ; LV ; end-diastolic pressure ;wall stress ; lung
NT-probNP levels ; dyspnea ; left ventricular dysfunction ; admission ; ed
pathological remodelling ; heart ; cardiac hypertrophy ; hz ; death ; fibrosis ; inflammation
hz-action cohort ; baseline ; hgb ; baseline ; HRQol ; kccq
circulating progenitor cells ; cps ; endothelial repair ; cardiovascular diseases
right ventricular ;rv ; body composition ; heart failure ; hz
ventricular assist device ;VAD ; extracorporeal membrane oxygenation ; ecmo ; renal function
american college of Cardiology ;American Heart association ;RAS ;RAS
report ; MS ; valve plasty ; MR ; LV ; disease
EO-cFUs ; mortality ; nondiabetic
implantable ; cardioverter-defibrillator deactivation ; heart failure
functional MS ; valve plasty ; annular size reduction ; MR ; LV ; dilated ; disease
heart failure ; hz
LV ; diastolic properties ; XO inhibition ; heart failure
SDQT ; hwt ; hm ; fixed-rate atrial
borderline
technique ; diffuse myocardial changes ; heart failure ; contrast agent ; breath-holding
bnp ; mortality
ct-d ; heart failure
expenditure ; health per capita ; income per capita ; hz
bt ; dt ; bt
pharmaceuticals ; hf
blood pressure control ; lipid-lowering ; smoking cessation ; foundation ;RAS
costs
cardiac magnetic resonance ; amyloidotic pattern ; multiple myeloma ; osteomedullary biopsy
implantable cardioverter-defibrillators ; iccds ; cardiac resynchronization therapy ; crt
Vascular endothelial growth factor blockade ; beta-blocker therapy ; cardiac function ; angiogenesis ; heart failure
low-sodium DASh ; diet ; diastolic function ; ventricular-arterial coupling ; hypertensive heart failure ; ejection fraction
diagnose ;HFpEF ; echo-doppler cardiography ; invasive haemodynamic assessment
hf ; hfpEF
PASp ; PASp
skeletal muscle sarcomere ; heart failure ; diabetes ; epicatechin-rich cocoa
physical ; outcomes ; medically ; hz
centrifugal flow pump ; hemocompatibility ; magnetically levitated rotor ; blood-flow paths ; artificial pulse
eplerenone ;HF-ref ; inducing hyperkalemia ; wf
mitochondrial complex ; activity ; ratio of phosphocreatine ; ATP
sst2 ; low-dose ; sst2 ; cardiovascular events
frail ; intermediate frail
QRs morphology ; cardiac resynchronization therapy ; crt
hff ; cardiac
RM ; admission ; heart failure
acute heart failure ; HF
embryonic gene ; pathological heart disease ; transcription factors ; driving
mdc ; change
lbc ; implantable ; cardioverter defibrillator-ct ; outcome ; outcome
isolated heart rate ; hz ; ivabradine ; afterload ; systolic heart failure
primary outcome ; cardiovascular death ; stroke ; heart failure ; myocardial infarction
heart failure ; hypertension ; mitral regurgitation ; significant mitral stenosis ; medical ; treatment ; heart failure
Cardiac-resynchronization therapy ; crt ; mortality ; chronic systolic heart failure
perk activation ; scn5a ; kv4.3 ; mRNAs ; transient receptor potential cation ; m7 ; tm7 ; mRNA
implantable cardioverter-defibrillator ; Heart function Clinic ; university health network ; toronto ; Canada
exercise-induced PASp ; pulmonary hypertension ; ventricular contractile reserve
MI ; metoprolol ; norepinephrine ; dopamine ; epinephrine
biomedical ; chm ; biomedical ; dm ; heart failure
st2 ; cardioprotective ; myocardium ; biomarker ; heart failure ; hz
cardiovascular ; Renal Atherosclerotic lesions ; coRAL ; stenting ;RAS
mortality ; heart failure ; hz ; implantable cardioverter defibrillators ; idocs
left-to-right interatrial shunting ; heart failure ; ejection fraction
Mediterranean and Dietary procedures to stop hypertension ;DASh ; mortality ; postmenopausal women ;HF
multiparametric echocardiographic score ; reverse remodeling ; ct
Yorkshire swine ; implanted ; pacemakers ; ventricularly paced ; induce heart failure
antagonists ; inhibitors ; renin-angiotensin-aldosterone ; sympathetic nervous systems ; CHF
hz ; hz ; epidemiology ; rheumatic fever
mortality ; readmissions ; costs
caloric ;diet ; aerobic ; exercise training ; exercise capacity ; hf
chronic heart failure ;HF ; hemodynamic disorder ; interconnected molecular pathways
medications ; heart failure ; ejection fraction
hfpEF ; diastolic filling time ; heart rate
mice ; cardiac myocyte-specific Mena overexpression ; tta ; cardiac pathology
antiplatelet agents ; combination ; anticoagulants ; vascular diseases
right Heart foundation working group ; step ; right heart failure
pb ; diagnostic
lbc ; QRs ; implantable ; cardioverter defibrillator-ct
echocardiography ; cardiac diameters ; cardiac function
medline ;EMBAse ; PsycINFO
functional capacity
medical
systolic HF ; cXL-1020 ; right heart ; systemic vascular resistance ; cardiac ; stroke
af ; heart failure ; financial burden
follow up ; body weight ; fm ; fm ;cc

ventricular ejection fraction ; left ventricular diastolic end diameter
outcomes ; concentric left ventricular hypertrophy ; heart failure ; ejection fraction
left ventricular ejection fraction ; heart failure ; preserved ejection fraction ; hf
β-adrenergic receptor blocker therapy ; myocardial perfusion ; neoangiogenesis ; heart
cardiac hypertrophy ; pressure-overload ; abdominal aortic constriction ; ac
baseline ; correlated ; baseline ; kccq ; exercise ; training ; HRQol
heart failure ; readmissions
Font failure ; hemodynamically ; heart failure ; systemic vascular resistance ; sv ; cardiac index
myofiber dynamics ; myofiber ; emd ; dyssynchronous HF
ankle-brachial index ; pulse-wave velocity ; coronary artery calcium scores
unfolded protein response ; ucp ; scn5a ; electric remodeling ; hz
intermacs ; interagency Registry for mechanically Assisted Circulatory support
allopurinol ; LV ; contractile function ;ROS ; myofilament ; sensitivity
techniques ; systolic function ;HFpEF ; axis function ; exercise
physicians ; heart failure
hf ; mortality ; hazard ratio ; mortality
hz ; hyperkalemia ; hypokalemia ; spironolactone ; derive
receptors ; receptor kinase-2
NT-probNP assay ; glycosylated
scn5a ; expression ; induced ; uPR
isolated heart transplant ; ect
bNP ; diastolic dysfunction
median rate ratio ; comorbidities
Medicare ; claims ; Medicare ; post-acute care transfer policy
heart failure ; compliance ; etidronate ; alendronate
metabolic exercise ; cardiac ; kidney index score
physical ; activity ; cf ; hf ; mortality
molecular pathways ; chronic heart failure ; ghf
dopamine ; nesiritide ; renal function
guideline ; anemia ; iron deficiency ; medline ; cochrane Library
kccq ; internal consistency ; hfpEF ; ronbach
implantable ; cardioverter defibrillator-crt ;LBb
principal mechanisms
follow-up times
chemotherapy ; trastuzumab ; comorbidities ; CHF ; international Classification of Diseases ; healthcare ; common procedure coding system codes
heart failure ;HF ;HF ; left ventricular ejection fraction ;LVf
hART ; hfpEF ;HF ; ejection fraction ; hf
conscious ; hz ; contractility ; end-systolic elastance ; venoarterial dilation
bone morphogenetic protein ; expression ; rRNA transcription ; shift ; heterochromatic chromatin
actin cytoskeleton ; mitochondrial function ; metabolism ; glycolysis ;gluconeogenesis ; citrate cycle
elevated resistin ; biomarker ; cardiotoxicity ; heart failure
extracellular matrix ; left ventricular biopsies ;issueFAXs ; technology
systolic HF ; Danish Heart Failure ; erd ; Danish Registry on dialysis
left ventricular assist devices ; lVADs ; heart failure ; pump dysfunction ; pump replacement
ST2 ; natriuretic peptide
biventricular pacing ; biVP ; cardiac output ; cardiac surgery
magnetically levitated lVAS ; mortality risk ; Seattle ; Heart Failure
New York Heart association ;NYha ; chronic heart failure ; ejection fraction
AlphaLISa ; immunoassays ; antibodies
creatinine ; bnp ; furosemide dose ; oxygen flow ; dobutamine ; norepinephrine
expression ; mistargeting ; regulation ; rad ; rGK protein
myocyte hypertrophy ; heart failure ; gene expression ; DNA
change
biomedical ; chm ; biomedical ; dm ; heart failure ; PubMed
sst2 ; high-dose BB ; sst2 ; BB ; cardiovascular
neurohormones ; adipokines ; body composition ; ccc ; fat free mass ; fm ; fat mass ;FM
cardiac plasma membrane ; s1p1 ; overstimulation ; heart failure
Sprague-dawley rats ; sham ; acf ; allopurinol
myocardial collagen ; myocardial delayed enhancement imaging
saxagliptin ; sitagliptin
catheter ablation ; af ; hff ; ventricular ; ejection fraction
BB therapy ; sst2 measurement ; chronic heart failure ; BB
ct
erd ; systolic HF ; egf
length-force relationship ; step ; rv ; LV
tunel assay ; apoptotic cells ; tunel-positive cells
functional efficacy ; hno ; myocardial function ; evidence ; hf
rvs ; explanted
transitions ; readmission rate ; congestive heart failure ; midwestern state ; south dakota
cardiomyocytes ; mechanical ; myocardium ; conditions
transplantation ; consultation ; operation
transplantation ; LV ; implantation ; heart failure
Nicorandil ; phosphocreatine ; adenine nucleotides ; mitochondrial oxidative phosphorylation capacity ; creatine kinase activity
intraclass correlation coefficient ; icc ; kappa coefficient ; change ; mdp
Hospitalized Heart Failure ; Saxagliptin ; sitagliptin ; antihyperglycemic Drugs
training ; chronic heart failure ; Heart failure ; exercise
national inpatient Registry ; rehospitalization ; stroke ; myocardial infarction ; heart failure ; cab
heart failure ; preserved ejection fraction ; hff ; heart failure ; overweight
Peritoneal dialysis ; pd ; diuretic ; overload ; heart failure ; hz
renal dysfunction ; heart failure ; hz ; renal disease ; erd
echocardiographic score ; LV ; reverse remodeling ; LV
Peripheral artery disease ;PAD ; heart failure ; hz ; hz ;PAD
readmission rates ; heart failure ; hz ; acute myocardial infarction ; am ; pneumonia
peripheral muscle pump ; cardiac filling ; exercise ; subpulmonary ventricle ; Font circulation
biological phenotype ; medical
SDwt ; hv ; hNorm ; β-adrenoceptor blockade ; esmolol
Cardiology ; national Cardiovascular Disease Registry ; clinical Excellence
medical ; mortality ; discharged ; heart failure
induced myocardial infarction ; heart failure ; bisoprolol
transitions ; health
CHF ; cardiac explant ; mechanisms ; regulation
tachycardia ; intravenous atropine ; cardiac vagal tone
report ; hno donor ; isolated myoctyes ; hearts ; heart failure ;HF

ms ; dynamic ; ms
chronic heart failure ; hz ; exercise
histological ; capillary ; coronary perfusion
mortality ; internists ; cardiologists
shuttle walk test ; body mass ; hand grip strength ; baseline
POc testing ; np ; consultation ; ed
heart failure ; CHAr programme ; candesartan ; Heart failure assessment ; Mortality ; Morbidity
Troponin t ; natriuretic peptide ; biomarker ; heart failure ; atherosclerosis
left-to-right interatrial shunting ; heart failure ; ejection fraction
physical ; bmi ; heart rate ; lying ; standing ; blood pressure ; valvular disease ; pulmonary congestion
myocardial extracellular matrix ; cardiac magnetic resonance ; pathobiology ;pathophysiology
aldosterone antagonist therapy ; heart failure ; post-myocardial infarction ; heart failure
Nicorandil ; heart rate ; aortic blood flow ; mitochondrial oxidative stress ; doxorubicin ; cardiotoxicity
heart failure ; left ventricular ejection ; spironolactone ; Kaiser Permanente Northern california
renal dysfunction ; cardiovascular events ;stroke ; myocardial infarction ; heart failure ; coronary artery bypass grafting
septum ;systolic ; posterior wall ; metoprolol
american college of Physicians ; acp ; evidence ; anemia ; iron deficiency ; heart disease
obese ; hff ; caloric ; aerobic ; exercise ; training ; peak VO2
economic ; Heart failure ; heart failure
HF ; HF ; hf
BAT ; pro-brain natriuretic peptide ; hospitalized ; hz
HR variability ; mortality ; am ; CHF ;LV dysfunction
exercise ; cell senescence ; active ; malignancies ; cancer ; prostate ; colon ; osteoporosis ; depression ; dementia
cardiac transplant ; ect ; transplant pool ; transplant
Fontan ; pf ; catheterization
ventricular assist devices ; cardiac nurses ; gastrointestinal bleeding
Lancet ; anoop Shah ; air pollution ; heart failure
anemia ;HF ; health-related quality of life ; hQol ;HF
cell therapy ; chronic heart failure ; chf
dyssynchronous nonfailing ;HF ; canine electromechanics ; combinations
rv failure ; chronic pulmonary arterial hypertension ; pac ; pulmonary embolism
rv ; pulmonary embolism
serum resistin levels ; anthracycline-containing chemotherapy ; cardiotoxicity
sst2 ; cardiovascular event rate
rad ; cardiomyopathy
ventricular ; fiber ; sheet orientation
baseline ; SDt-to-SDr ratio ; hwt ; hwt
renin-angiotensin system blocker ; beta-blocker therapy ; heart failure ; left ventricular ejection fractions
exercise ; medical ; Cardiac function ; Breath ; Lung congestion ;ACTRN
electrical stimulation ; peripheral muscles ; endothelial function ; emotional ; heart failure ; left ventricular ejection fraction
tachycardic response ; methylatropine ; bradycardic response ; propranolol ; sympathetic tone
cardiac resynchronization therapy ; crt ; heart failure ; hz ; QRs ; ejection fraction
flow reserve ; positron emission tomography ; ischemia ; bottleneck stenting ; left ventricle ;LAD
mitochondrial oxidative phosphorylation capacity ; creatine kinase activity ; oxidative stress markers ; DNA fragmentation
spironolactone ; death ; hyperkalemia ; kidney injury
cardiovascular mortality ; hz ; exercise
neprilysin inhibitors ; natriuretic peptide system ; atrial natriuretic peptide ; natriuretic peptide
tpacse ; pasp relationship ; hff ; hfpEF ; resolution
HF-action ;HF ; ejection fraction ; exercise
epigenetic ; writer ;histone acetyltransferases ; epigenetic ;erasers ;histone deacetylases ; cardiac
NT-probNP levels ; mortality ;HF
haematopoietic cell transplantation ; ht ; congestive heart failure ; chf ; ht ; anthracyclines
cardioprotective effect ; nicorandil ; hemodynamic ; mitochondrial dysfunction ; administration ; doxorubicin
mir-25 ; cardiac dysfunction ; murine myocardium ; heart failure
herbal medicine ; chm ; dilated cardiomyopathy ; dm ; heart failure
hypertension ; diabetes mellitus ; systolic ; diastolic murmurs
postoperative ; hypoalbuminemia ; albumin concentration
electrical activation ; dyssynchronous heart failure ; hz ; electromechanical ; heart
heart failure ;heart team ; cardiologists ; cardiovascular surgeons ; medical
Baroreflex sensitivity ; heart rate variability ; hv ; sham-inv ; sham levels ; renal DNx
bisphosphonates ; alendronate ; etidronate ; heart failure ; compliance
nurse ; cognitive impairment ; heart failure
carvedilol ; β-blocker ; β-blocker metoprolol ; thromboembolic events ; heart failure
baseline ; cardiac transplant ; ect
mortality
heart failure ;HF ; evidence ;HF
arrhythmia substrate ; am ; HR ; fatal arrhythmia events
doxorubicin-induced cardiotoxicity ; Hum-retn mice ; resistin ; retn
hypertension ; hff ; DASh ; rs ; sodium
emd ; dyssynchronous HF
diastolic dysfunction ; pathophysiology ; hfpEF ; non-diastolic abnormalities ; cardiovascular function
ejection fraction ; cardiac index ; inotropes ; medical ; transplant
high-density lipoprotein ;HDl ; endothelial-protective ; endothelial cell ; nitric oxide
hHF ; saxagliptin ; sitagliptin ; antihyperglycemic agents
degs ; ischemic ; heart failure ; heart failure
insulin resistance ; diabetes ; insulin receptor substrates ; irs1 ; irs2 ; insulin-signaling ; metabolism
significant ; outcome ratings ; admission to discharge ; heart failure ;HF ; Nursing outcomes Classification ; noc
fluo-cAMP binding ; phosphomimic ; ser77 ; ser83 ; mutant ; RIα proteins ; double mutant ; wt RIα
mortality ; lVAD implantation ;hazard ratio
systolic heart failure ; QRs ; ct ; rate of death ; heart failure ; mortality
cox regression models ; propensity score ; oral glucocorticoid ; hz ; loop ; diuretics
functional electrical stimulation ; fes ; exercise capacity ; emotional ; endothelial function ; heart failure ; systolic function
dialysis ;HF ; mortality ;HF
bleeding ; driveline infection ; gastrointestinal bleeding ; stroke ; Rank Score
Beta blockers ; mortality ; readmissions ; heart failure ; ejection fraction ; hf ; heart rate
dyssynchronous HF ; electromechanical delay ; emd ; myocyte depolarization ; myofiber
QRs morphology ; cardiac resynchronization therapy ; resynchronization-Defibrillation ; ambulatory Heart Failure trial ;RAF
biomarker ; therapeutic potential
SAF ; liver texture ; nodularity
transplant ; pd ; hf ; volume management ; post-PD
weak grip strength ; physical ; activity ; weight loss
ct-d ; icc ; ct-d
eds ; discharge ; heart failure ; ED ; readmissions ; ED
right heart failure ; refractory cardiogenic shock ; heart ; corporeal membrane oxygenation ; ecmo ; cp ;ICU
report ; right atrial myxoma ; embolism ; pulmonary arteries ; right atrial mass removal ; pulmonary embolectomy
heart disease ; hz
heart magnetic resonance imaging ; compliance ; heart failure ; arrhythmias
ejection fraction ; pre-PD ; NYha ; right ventricular dysfunction
cps ; epacs ; vgf2
expression ; Bax ; mRNA ; expression ; heart failure ; ratio ; bcl-2 ; bax
nitroxyl ; Angeli ; inotropic ; lusitropic ; vasodilator effects ; cAMP
anticoagulation ; rate control ; cardiovascular complications ;stroke ; cardiovascular death ; acute heart failure ; atrial fibrillation ; af
evidence ; cost-effectiveness ; continuous-flow lVADs ; HeartMate ; HeartWare ; bt ; dt
baseline
keletal muscle mass ; relative appendicular lean mass index
DASh ; mortality ; hz ; diet scores
mortality ; mortality
bNP ; bNP ; mortality
cardiovascular diseases ; heart failure ; hz ; hz
heart failure ; left ventricular systolic dysfunction ; BB
ccnka polymorphism ; heart failure ; glomerular filtration rate ; reNAStur
ST2 ; functional capacity ;HF
cardiac ; VEGF expression ; Akt ; endothelial no synthase activation ; hearts
expression ; cardiomyocytes ; drug ; phenylephrine-induced genes
exercise-induced PASp ; right ventricular contractile reserve ; exercise-induced PASp
Gene expression profile ; gse9128 ; Gene Expression Omnibus ; heart failure
cardiac ; insulin-resistance ; insulin-stimulated rates ; glycolysis ; glucose oxidation ; plasma membrane translocation ; glucose transporter
baseline ; post-DASh ; rs ; brachial ; central blood pressure ; radial arterial tonometry ; cardiovascular function ; echocardiographic
Psychosocial factors ; exercise ; Heart Failure ; Heart Failure ; exercise ; hz-action
derivation cohort ; coronary angiography ; primary ; systolic HF ; etiology
arterial elastance ; end-systolic elastance ; ees ; ventricular-arterial coupling ; techniques
rhythm control therapy ; rhythm control therapy ; antiarrhythmic drugs ; catheter ablation ; electrocardiographic device ; rhythm
cells ; angiotensin II ; angII ; hypoxia ; activators ; scn5a mRNA ; splicing ; induced ; scn5a
evidence ;HF ; ejection fraction ;HFrEF ;HF ; ejection fraction ;HFpEF
bridging therapy ; ischemic right heart failure ; cardiogenic shock ; reperfusion therapy
heart failure ; left ventricular ejection fraction ; fes ; exercise capacity ; endothelial function ; hfpEF
expenditures ; noncardiovascular diagnoses ; implantable ; cardiac arrhythmia devices ; noncardiovascular drugs
intubation rates
raloxifene ; mechanism of action ; heart failure
hearts ; tta ; tgtetMena mice ; heart mass ; transgenic mice
hf ; exercise ; respiratory gas ; baseline
drugs ; heart failure ; biomedical
wasting of fat ; lean mass ; fat loss ; adipose tissue ; cardioprotective ; hz
hearts ; nucleolin ; chamber patterning ; cardiac looping ; myocyte differentiation
black race ;HF ; exercise ; HF ; mortality ; exercise training
significant ; acute myocardial infarction ; congestive heart failure
Macrophages ; cardiomyocytes ; Hum-retn mice ; doxorubicin ; hretn ; mRNA ; expression
lVADs ; HeartMate II ; thoratec Corp ; pleasanton ; calif ; hVAD ; HeartWare intl ; inc ; Framingham ; mass
FM ; NPs ; baseline ; FM ; fm ; nps
sympathetic tone ; parasympathetic tone ; heart rate ; metoprolol ; atropine
eh ; hfpEF ; pathophysiologically ; hf ; hf ; therapy
collected ; hz ; immunoreactive ; NT-probNP
beat-to-beat QT interval ; eCGs ; baseline ; esmolol ; isoprenaline ; atropine infusion

power spectral ; low-frequency ; high-frequency ;LF ;HF ; CHF-inv ; sham-inv ; sham levels
contractility ; ventricular-arterial coupling
change ; readmissions ; hospital
natriuretic peptide ; misdiagnosis ; heart failure ; hz
cardiac magnetic resonance ; hff ; biomarker ; hff
left ventricular ejection fraction ; New York Heart association ; hz ; exercise
myocardial dd ; collagen deposition ; titin ; diabetic ; zSF1 ; heart failure ; ejection fraction
cardiac tissue ; bet inhibition ; pathological cardiac gene expression
health
systolic blood pressure ; left ventricular ;LV ; hypertrophy
conditional ; hand2 ; pressure-overload-induced hypertrophy ; fibrosis ; ventricular dysfunction ; fetal gene
admission ; ed ; hz
Peak oxygen consumption ;VO2max ; hz
death ;heart failure ; death ; noncardiac ; cardiac transplant
frailty ; health ; physical performance Battery ; hbc Battery ; Gill index ; hz
epigenetic readers ; cardiac biology ; cardiac gene control ; chromatin-dependent signal transduction ; abrogate ; pathological gene expression ; hz
rule ; CAD ; angiography ; systolic HF ; cost
load-corrected chronotropic response ; heart rate ; exercise ; baseline ; follow-up tests ; heart rate ; exercise
hospital ; gastrointestinal bleeding ; died ; ventricular tachycardia storm ; heart failure
percutaneous revascularization ; angioplasty ; stenting
hz ; t2d ;ERC ; treadmill testing ;VO2max ; oxygen consumption ; Skm biopsies
hz ; QRs ; uct ; reverse remodeling ; LV ; systolic dysfunction
rv ; lVAD ; cardiogenic shock ; myocardial infarction ; heart failure

Gill index
hz ; am
Chronic heart failure ; chf ; disease ; anemia ; insulin resistance ; autonomic dysbalance ; cardiac cachexia
β-AR stimulation ; catecholamine infusions ; pde2 ; expression ; cAMP hydrolytic activity ; blunted cardiac
chronic pAH ; rv ; pharmacologic ; rv failure management ; pAH
zf1 ; heart failure ; ejection fraction ; lung weight ; left ventricular ejection fraction ; left ventricular
Xanthine oxidase ;XO ; ventricular ; myocytes ; overload ; mitral regurgitation ; aortocaval fistula ; acf
free-breathing pulse sequence ; myocardial t1 changes ; swine model ; tachycardia-induced heart failure
pf ; New York Heart association
medication
mortality ; physicians
western Australian ; administrative ; health ; hz ;AMI
report ; turkey
eds ; diagnosis ; heart failure
outcome measures ; science ; treatment ; hz
miRNAs ; noncoding RNAs ; expression ; binding ; messenger RNA
hfpEF ; ivabradine
cardiac ; cardiac ; cardiac functions ; myocardial infarction
nps ; heart failure ; pulmonary embolism ; diabetes ; chemotherapy
pathophysiology ;HF ; medical ; pathophysiologic state
outcome measures ; heart failure ;HF ; acute myocardial infarction ; am ; pneumonia ; pna
mortality ; healthcare ; telehealth ; congestive heart failure ; chronic obstructive pulmonary disease ; diabetes mellitus
inhibitor jq1 ;BETs ; chromatin ; downstream ; RNA polymerase II
catheter ablation ; atrial fibrillation ; af ; heart failure ; ejection fraction ; hff
heart failure ; ejection fraction ; hf ; health
coronary syndromes ; coronary interventions
cyclic adenosine monophosphate ; cAMP ; guanosine monophosphate ; cgm ; hearts
RA ; methotrexate ; tnf ; non-biological disease ; antirheumatic drug ; nbDMARD
intestinal dysfunction ; intestinal barrier ; chronic inflammatory state ; catabolic ;anabolic imbalance ; cardiac cachexia ; CHF
report ; ischemic-hypertensive cardiomyiopathy ; angina ; inducible myocardial ischemia ; coronary arteries
sphingosine-1-phosphate receptor ; β1-adrenergic receptor ; receptors ; heart
septal ; pcwp
atrial fibrillation ; carvedilol ; metoprolol
Bradycardia induced ; intravenous metoprolol ; cardiac sympathetic tone ; rabbits ; sham-inv
nordic walking ; cardiac rehabilitation ; functional capacity ; heart failure
prescribed ; pharmacological treatment ; left ventricular function assessment
grs ; LVf ; cv ; prognostic benefit ; echocardiographic systolic
ERC induced recovery ; DAPc ; sarcomeric microstructure ; Skm ; myofibre regeneration
signalling cascades ; microRNAs ; expression ; bHLh ; transcription factor ; hand2 ; postnatal mammalian myocardium ; embryonic gene ; heart failure
rad Q66p ; inhibitory ; rad ; cav1.2 ; cav1.3 ; isoforms ; heart
lx ;LAD ; stenting ; left ventricle ; lx ;LAD
compliance ; LV ; end-diastolic volume ; LV ; end-diastolic pressure ; hg ; coefficient
mva ; implantation ; leaflet motion ; edge-to-edge anastomosis
hz ; New York Heart association ;NYha ; hz ; self-management counseling ; outcome ; hz
cardiac function ; echocardiography ; diastolic dysfunction ; systolic dysfunction ; ejection fraction
BET ; bromodomain proteins ;BETs ; acetyl-lysine reader proteins ; hf ; pathogenesis ; hf
blood transfusions ; erythropoiesis-stimulating agents ; anemia ; congestive heart failure ; coronary heart disease ; transfusion
grade
hz
foundation ; right heart ; circulatory failure ; mechanisms of disease ; right heart
voltage-gated ; ventricular action potentials ; excitation-contraction ; coupling ; myocardium
ivabradine ; exercise capacity ; left ventricular filling ; heart failure ; ejection fraction ; hf
aldosterone antagonism ; heart failure ; aldosterone ; neurohormone ; electrolytes ; heart failure ; systolic dysfunction
bp ; glomerular filtration rate ; hypertension ; transmitral ; diastolic mitral annular velocity
AT1 receptors ; neprilysin blocks ; renin-angiotensin-aldosteron ;RAS ; axis ; natural vasodilatory ; diuretic effect ; natriuretic peptides
β-blockade ; disease progression ; cAMP-dependent protein kinase ; pka ; downstream ; β-adrenergic receptor activation
evidence ; erythropoiesis-stimulating agent therapy ; venous thromboembolism
black race ; mortality ;hazard ratio ; cardiovascular mortality ; hospitalization
chronic myocardial ischemia ; sten ; polytetrafluoroethylene tube
genetic ; CHF ; genetic
multivariable logistic ; peak oxygen uptake ; metabolic exercise ; cardiac ; kidney index score ; hz
heart failure ;HF ; tumor necrosis factor ; tnf ; tnf ;HF
Centers for Medicare and Medicaid services ; ms ; publicly ; mortality ; readmission rates ; penalties
follow-up ; physician ; discharge ; outcome ; death
logistic regression ; rule ; CAD ; stenosis ; CAD ; CAD ; anterior descending artery
signal transduction cascade ; transcription factors ; pathological ; cardiomyocytes ; transcription factors ; epigenetic changes
hypertensive hff ; sodium-restricted DASh ; ventricular diastolic function ; arterial elastance ; ventricular-arterial coupling
combination ; surgery ; diastolic mitral valve tethering ; anterior leaflet opening ; papillary muscles ; left ventricular
Randomized aldactone evaluation study ; heart failure ; aldosterone antagonist ; spironolactone ; mortality
heart failure ; acute myocardial infarction ; acute myocardial infarction ; western australia
CHF ; ht ; anthracycline metabolism ; iron homeostasis ; anti-oxidant defence ; myocardial remodelling
medication ; nonadherence
pathophysiological
lVAD ; surgery ; albumin levels ; hypoalbuminemia ; surgery
creatinine ; significant ; post-transplant mortality
death ; glomerular filtration rate ;odds ratio
hm II ; HeartWare ; economic ; hm
dopamine ; nesiritide ; renal function ; heart failure ; renal dysfunction
HR variability ;turbulence ; HR variability ;turbulence ; cardiac
complications ; implantation ; lVAD ; transplantation ; bt ; dt ; medical
radial artery tonometry ; admission ; PH ;ICU
magnetically levitated centrifugal-flow chronic lVAS
eRK1/2 ; signalosome ; scaffold protein drives ; kinases ; sequential phosphorylation
Breast cancer ; Medicare ; breast cancer ; chemotherapy ; er-Medicare ; Texas cancer Registry-Medicare
ejection fraction ; natriuretic peptide levels ; heart failure ; outcomes ; get with the guideline-heart failure Registry
cardiomyocytes ; pde2 ; activity ; cgm synthesis ; nitric oxide donors ; pde2
l-dko ; cardiac ; irs1 ; irs2 ; heart failure ; cardiac energy metabolism ; gene expression ; protein kinase
HDl ; phosphorylation ; eNOS-Ser ; p70s6k-Ser
PASp
sts ; hm ; sts
ventricular myocytes
administrative ; Alberta ; discharged ; hospital ; heart failure
heart failure ; histologically ; myocardial collagen ; heart failure
ct ; time to death ; hz ;hazard ratio ; LVf
beta1-adrenergic receptor ; sphingosine-1-phosphate receptor ; reciprocal downregulation ; cardiac hypertrophic response ; heart failure ; cardiac gene therapy
relative risk ; r ; heart failure ; bisphophonates ; rr ; hazard ratio
Medicare ; enrolled ; Centers for Medicare ; Medicaid services
guideline ; heart failure ; Clinical practice guideline ; cpg ; heart failure ; hz
nicorandil ; doxorubicin-induced heart failure ; hemodynamic ; mitochondrial dysfunction ; antitumor activity
kccq ; New York ; Heart association ; hzpEF ; hz
Rhythm control therapy ; af ; atrial ; sinus rhythm ; rhythm control ; rate control
acute heart failure ; renal dysfunction ; dopamine ; nesiritide ; renal function ; diuretic therapy
HF ; body composition ; skinfold ; dual-energy x-ray absorptiometry ; echocardiography ; blood testing
heart failure
acp ; red blood cell transfusion ; hemoglobin threshold ; hemoglobin levels ; coronary heart disease
heart failure ;HF ; conditions ; myocardial infarction ; pneumonia ; conditions
implanted ; haemodynamic ; heart failure ; ejection fraction
correlated ; right ventricular-pulmonary arterial coupling ; pulmonarary vascular resistance ; right ventricular ejection fraction
ventricular assist devices ; lVADs ; chronic end-stage heart failure ; bridge to transplantation ; bt ; transplant-ineligible patients ; dt
Caloric restriction ; aerobic ; exercise ; Peak oxygen consumption ; Heart Failure ; ejection Fraction
carvedilol ; metoprolol ; implantable ; cardioverter-defibrillator therapy ; MAD-ct ; multicenter Automatic Defibrillator implantation ; Cardiac resynchronization Therapy
oral glucocorticoids ; hz
HR ; ivabradine ; ea ;TAC
carvedilol ; metoprolol ;hazard ratio
ethnic groups ; chm ; dm ; heart failure
testosterone ; exercise ; health outcomes ; CHF ; testosterone
change ; peak VO2 ; lean body mass ; change ; thigh muscle ; intermuscular fat ratio
guidelines-heart Failure ; hz ; borderline
economic ; Heart failure ; cost-effectiveness ; disease management ; heart failure
hfPSI ; medical ; HF ; outpatients ; hf ; health systems
cardiac insulin-resistance ; mitochondrial oxidative metabolism ; metabolic changes ; cardiac hypertrophy ; energy deficit ; hypertrophy ; heart failure
multivariate cox model ; exercise ;hazard ratio
pathophysiology ; heart failure ; ejection fraction ; hff ; myocardial extracellular matrix accumulation
combination ; surgery ; diastolic mitral valve tethering ; anterior leaflet opening ; papillary muscles ; left ventricular ;LV
breathing control ; cardiac arrest ; advantage ; pulseless ventricular fibrillation ;pvf ; implanted ; cardioverter-defibrillator device
rad ; rg ; rem ; rem2 ; rad ; gem ;Kir ; monomeric g proteins ; ventricular action potential duration ; coupling gain ; cardiac ; activity
acetylcholinesterase inhibitor pyridostigmine ; sympathovagal balance ; cardiac remodeling ; cardiac function ; hz ; myocardial infarction
cardiac sympathetic activity ; i-meta-iodobenzylguanidine
stockholm web-system for enhancement and development of evidence-based care ; Heart disease ; evaluations registry ; primary isolated cag ; sweden
LVf ; reverse ; death ; hz ;hazard ratio
brain natriuretic peptide ; bNP ; bNP ; bnp
coprimary end points ; urine volume ; change ; serum cystatin ; enrollment ;renal function
tpacse ; longitudinal rv fiber shortening ; pasp ;force ; rv ; rv ; length-force relationship
pde superfamily ; pde2 ; cgm ; cAMP hydrolysis ; cross talk ; cgm ; cAMP
pbp ; pb ; adiponectin ; CHF ; bmi ; FM
admissions
mitochondrial-targeted antioxidant ; Szeto-schiller ; ss20 ; cardiac function ; proteomic remodeling
financial ; cardiac arrest ; cardiopulmonary resuscitation ; cp ; posterior wall infarction ; cardiac
hyperkalemia ; mineralocorticoid receptor antagonists ; mineralocorticoid receptor antagonists ; heart failure ; hz
evidence ; acp ; erythropoiesis-stimulating agents ; anemia ; congestive heart failure ; coronary heart disease
diabetes ; saxagliptin ; sitagliptin ; pioglitazone ; sulfonylureas ; insulin
uPR ; scn5a ; ventricular systolic HF ; induced pluripotent stem cell-derived cardiomyocytes
heart failure ;HF ; ejection fraction ; erf ; renin-angiotensin system ;RAS ; mortality ; readmissions
financial incentives ; cochrane Effective practice and organisation of care taxonomy
coPD ; CHF ; cf ; icc ; kappa coefficients
stable heart failure ; left ventricular ejection ; aerobic ; dynamic resistance training
implantable ; cardioverter-defibrillator deactivation ; implant ; change
heart failure ; myocardial function ; contracting ventricles
implantable cardioverter-defibrillator deactivation ; implantable cardioverter-defibrillator shocks
left ventricular longitudinal systolic strain ; grs ; left ventricular mechanics ; cardiovascular ;CV ; atrial fibrillation ; af
mouse Rad ; murine ; rad ; currents ; cav1.2 ; cav1.3 ; rad
hz
research design ; Medicare ; acute care hospital ; hz ;AMI ; pna
cardiovascular events ; baseline ; sst2 ; metoprolol succinate
ctnt ; NT-probNP ; aRIC HF model ; acs ; NRIs
HF ; HF ; HF ; change ; HF ; MI
HDl ; phosphorylation ; eNOS-Ser ; phosphorylation ; eNOS-Thr ; HDl
carvedilol ; von wilebrand factor ; metoprolol ; β2-adrenergic receptor haplotype
heart failure ;HF ; hypertensive heart disease ; hd ; pathophysiology ; hd
sarcoplasmic reticular ; rs ; protein ; pump ; phospholamban ; infarcted hearts ; metoprolol
temps up & go ; tug ; chronic obstructive pulmonary disease ; cop ; chronic heart failure ; chf ; chronic renal failure ; crf
exercise ; intramuscular testosterone supplementation ; chronic heart failure ; chf ; testosterone status ; health outcomes
hf ; LVEF ; mortality ; LVEF ; LVEF ; mortality
grs ; left ventricular ejection fraction ;LVf ; systolic mitral annulus velocity ; cv
heart failure ;HF ; natriuretic peptide ; bnp ; ejection fraction ; f ; hz
RM ; home telemonitoring ; implanted monitoring devices ; medical ; sts ; contact ; hz
cox regression ; beta-blockers ; beta-blockers ; antitachycardia pacing ; acp ; shock therapy
ethically ; religious beliefs ; legal ; decisions
prescribing ; medical records
cost ; rhythm-control ; rate-control
ventricular ejection fraction ; egf
cRF ; hazard ratios ; fit ; overweight ; body mass index ; obese
primary outcome ; ct ; hazard ratio
hzp ; blood urea nitrogen ; natriuretic peptide ; New York Heart association ; diabetes ; atrial fibrillation
Medicare ; Patient safety monitoring system ; mpsm ; adverse event rates ; acute myocardial infarction ; congestive heart failure ; pneumonia ; conditions ; surgery
functional capacity ; peak VO2
heart failure ; ejection fraction
case-fatality rate ;HF ; HF ; case-fatality rate
CHF ; anthracycline exposure ; stem cell
tension ; muscle strips ; kcl-KI ; treatment ; titin ; titin ; extracellular matrix
reversibility ; heart failure ; myocardial infarction ; m ; β-adrenoceptor blockade ; infarcted ; metoprolol
aerobic ; resistance training ; exercise capacity ; muscle strength ; cardiac ; t-probp ; inflammatory ; il6 ; hscrp
readmission metrics ; all-cause readmission ; acr ; Preventable Readmission ; pdp ; centers for Medicare and Medicaid ; 30-day readmission ; cms
heart failure ; ed ; correlation coefficient
exercise ; walking ; Minnesota ; exercise
arginine vasopressin ; aVP ; physiologic ; CHF ; aVP ; vasopressin receptor antagonist therapy ; CHF
angiotensin-converting enzyme inhibitors ;angiotensin receptor blockers ; β-blockers ; heart failure ; ejection fraction
physical ; implantable defibrillators ; circulatory ; transplantation ; heart failure
sodium-restricted dietary ; hypertension diet ;DASh ; rs ; left ventricular diastolic function ; arterial elastance ; ventricular-arterial coupling ; hff
right ventricular pacing ; gene expressions ; Bax ; bcl-2 ; Caspase-3 ; RTq- pcr ; interventricular septum biopsies ; beagle dogs ; heart failure
Rats ; hearts ; activity ; phosphocreatine ; adenine nucleotides ; cytochrome ; bcl2 ; Bax ; caspase ; expression
metoprolol ; carvedilol ; sympathetic activity ; von wilebrand factor
hz ; RELAx-aHF ; stannard ; prONTO ; enrollment
hz ; international Classification of Diseases ; Ninth revision ; principal discharge
pulmonary capillary wedge pressure ; baseline ; right atrial pressure ; pulmonary arterial pressure ; pulmonary resistance
rad ; q65p ; movement ; wild-type rad ; q65p ; inhibition ; rGK proteins
SS20 ; heart failure ; proteomics ; cytoskeleton pathways ; SS20 ; mitochondrial ; metabolic pathways
aortic insufficiency ;AI ; mechanical circulatory ; flow ; left ventricular assist devices ; lVADs ; pulsatile devices
administration ; pyridostigmine ; coronary artery ligation ; cardiac vagal ; sympathetic tone ; cardiac remodeling ; left ventricular dysfunction ; hz
follow-up visits
heart failure ; heart failure
heart failure discharges ; university of Connecticut ; health center
New York ; Heart association ;NYha ; Heart Failure ; eplerenone ; Heart Failure Medicines ; pharis-h study
echocardiograms ; left ventricular base ; midpapillary ; baseline ; icc occlusion ; BiVP ; ste ; twist ; basal rotations ; rs
evidence ; drugs ; raas ; direct renin inhibitors ; neutral endopeptidase inhibitors ; vasopeptidase inhibitors ; angiotensin receptor blockers
acute heart failure ;HF ; pharmacologic ; calcium-sensitizing agents ; endothelin ; vasopressin ; adenosine
hz ; induced ; mice ; phenylephrine ; haemodynamic stress ; transverse aortic constriction ;TAC ; jq1 ; cardiac hypertrophy
Muscle aerobic capacity ; postexercise phosphocreatine resynthesis ; Fontan
i-mig ; cardiac washout ; carvedilol ; metoprolol ; treatment ; β2-adrenergic receptor haplotype
treatment ; acute myocardial infarction ; am ; heart failure ; hz ; am
h-dko ; ventricular mass ; cardiac apoptosis ; fibrosis ; Akt ; voorkhead box ; cardiac metabolic gene expression ; ATP
bottleneck stent ; implanted ; anterior descending ; lad ; proximal circumflex artery ; lx ; lx ; lad ; pigs
heart failure ; hf ; dipeptidyl peptidase-4 ; dp-4 ; antihyperglycemic agents
multivariable cox modeling ; Heart Failure Patient Severity index ; hzPSI ; university of Michigan ; hz ; primary outcome
pde2 ; overexpression ; cardiomyocytes ; cAMP ; ca2 ; inotropic effect ; basal contractility
ATP ; shock therapy
Cardiac resynchronization therapy ; ct ; heart failure ; hz ; outcomes ; ct ; dialysis
joint ; cardiorespiratory fitness ; crf ; body mass index ; heart failure ;HF ; mortality ; cardiovascular risk factors ;HF mortality
eplerenone ; hyperkalemia ; renal function ; emPHAs-HF ; eplerenone ; Heart Failure
Heart rate ; hz ; cardiac ; acute myocardial infarction ; am ; congestive heart failure ; ghf ; left ventricular ;LV
neonatal rat ; ventricular cardiomyocytes ; chronic insulin exposure ; irs1 ; irs2 ; insulin action ; fundamental mechanism of cardiac dysfunction ; insulin resistance ; diabetes
echocardiograms ; left ventricular midpapillary level ; atrioventricular delay ; avd ; interventricular delay ; vd ; ste ; radial strain ;RS
New York Heart association ;NYha ; functional ; hz ; ejection fractions ; chronic stable guideline-directed medical therapy ; ght ; united states ; Canada ; europe
lbc ; ms ; outcome
dyssynchronous HF ; myofiber ; velocity ; septum ; myofiber ; stretch rate
shotgun proteomics ; proteomics ; transverse aortic constriction ;TAC ; heart failure
transforming growth factor ; tgf ; epithelial ; mesenchymal transition markers ; expression ; pluripotency markers
pka ; change ; regulatory ;RI ; expression ; phosphorylation ; hz
hf ; left ventricular ejection fraction ; hfpEF ; left ventricular ejection fraction ; β-blocker dose changes ; hf
g-protein-coupled receptors ; physiological ; regulation ; hearts ; chronic β-adrenergic receptor stimulation ; postischemic heart failure
concentric remodeling ; cr ; concentric hypertrophy ; left ventricular ;LV ; heart failure ; ejection fraction ; hf ; eccentric hypertrophy ;EH
exercise ; exercise
RV ; cachexia ;hazard ratio
resting HR ; follow-up ; baseline ; VO2max ; resting HR
tgf-β inhibition ; cardiac progenitor function
NT-ProbNP ; inflammatory biomarkers ; hscrp ; il6 ; hscrp
BETs ; neurohormonally induced heart disease ; jq1 ; hypertrophy ; cardiomyocytes
BAT ; exercise capacity ; natriuretic peptide ; heart failure ; hospitalizations ; ght-treated NYha ; functional class III hz
activation ; malondialdehyde bound
significant ; mlf ; exercise ; diet ; exercise ; diet
nonpace ; ham-innervated ; ham-inv
hbc Battery score ; HF ; health ; HF ; significant ; death
ejection fraction ; frail ; biological phenotype ; death ; frailty ; death
hemoglobin ; HRQol ; HRQol ; Heart Failure ; exercise training
atrial Fibrillation ; congestive Heart Failure trial ; health care ; expenditures ; Québec ; rhythm ; rate-control
heart failure ; compliance ; myocardial ischaemia ; bradyarrhythmias ; valvular regurgitation ; pulmonary embolism ; infection ; renal dysfunction
report ; calcineurin ;fat signalling ; mir-25 ; expression ; basic helix-loop-helix ; bHLh ; transcription factor ; hand ; myocardium
exercise time ; psss ; btes ; exercise time ; psss ; btes
NT-probNP cutoff point ; admission
prognostic power ; HR ; fractal scaling
diastolic function ; diastolic filling ;viscoelastic ; doppler mitral inflow velocity
heart failure ; hz ; ventricular tachycardia ; hz ; hearts ; nordm
grs ; chronic heart failure ; hypertension ; diabetes ; stroke score ; glomerular filtration rate ; LVf ; cv
VAD ; ventricular assist device ; ecmo ; extracorporeal membrane oxygenation membrane ; ecmo ;VAD
ischemic events ; ies ; ischemic cardiomyopathy ; icc ; cardiac resynchronization therapy ; defibrillator ; crt-d
heart failure ; disease management ; evidence-based treatments ; health care system
heart failure ; mouse ; transgenic ; Retn gene ; hum-retn mice
angiotensin-converting enzyme inhibitors ;angiotensin receptors blockers
TTA ; tgtetMena ; cardiac injury ; ejection fraction ; heart dilatation ; hypertrophy ; transverse aortic constriction ;TAC
resynchronization-Defibrillation ; ambulatory Heart Failure trial ; implantable ; cardioverter defibrillator-crt ; mortality ; heart failure
heart failure ; italy ; confirmatory factor analysis ; cfa ; schf ; self-care maintenance ; self-care management ; self-care confidence
mwt ; NYha ; hfpEF ; hff ; prescribed ; hfpEF ; death ; hf
renal dysfunction ; chronic obstructive pulmonary disease ; diabetes ; peripheral vascular disease ; left ventricular ejection fraction ; iCD shocks ; mortality ; ischemic cardiomyopathy
Raf-MEK1/2-erk1/2 scaffold proteins ; cardiac remodelling
CHF ; testosterone levels ; exercise ; testosterone
ms ; dynamic ; treatment ; heart failure ; hz ; ms ; hz ; MR ; prolapse ; mitral valve
New York Heart association ; kccq ; Spearman ; HF ; hfpEF
angiotensin converting enzyme inhibitor ; angiotensin-receptor blockers ; β-blockers ; heart failure ; medical records
c57b ; infusion ; uninephrectomy ; ANG II infusion ; salt loading ; ANG II infusion ; uninephrectomy ; salt loading
early transmitral blood flow velocity ; doppler ; early diastolic mitral annulus velocity ; pulmonary capillary wedge pressure ; pcp ; systolic heart failure ;HF
systolic indices ;LV ; ejection fraction ; strain rate ; systole ; diastolic indices ; strain rate ; diastole ; transmitral flow ; sinus rhythm
VO2 ; exercise ; body mass ; diet ; body mass
hz ; hz
AMI ; hospital
mass spectrometry ; circulating ; NT-probNP ; physiological proteolysis
ctnt ; report ; ctnt ; NT-probNP ;HF prediction model
hfpEF ; New York ; Heart association ; mean ejection fraction ; fes
depressed left ventricular ;LV ; systolic pressure ; ejection fraction ; cardiac output ; LV ; end-diastolic pressure ; MI ; metoprolol
baroreflex activity Therapy ; Heart failure ; ejection Fraction ; carotid baroreflex activation therapy ; heart failure ; hz
enrollment
hf ; risk factors ; raised blood glucose levels ; obesity ; tobacco ; aging ; systemic hypertension ; rheumatic fever ; chagas ; disease ; la
cf ; overweight ; obese body mass index
kccq ; hfpEF ;log
baseline ; egf ; egf ; egf ; hypertension ; diuretics ; ESRD
myocardial phosphodiesterase-2 ; pde2 ; heart failure ; hz ; pde2-mediated effects ; beta-adrenergic receptor ; cardiomyocytes
heart failure ; cardiac resynchronization therapy ; defibrillator ; implantable ; cardioverter-defibrillator device ; carvedilol ; ATP ; shock therapy ; metoprolol
ERC ; epicatechin-rich cocoa ; Skm mitochondrial ; taub ; ramirez-sanchez ; ciaraldi ; perkins ; Murphy ; naviaux ; Hogan ; ceballos ; maisel ; Henry
urgent readmission
overexpression ;TAC ; surgery ; cardiac hypertrophy ; TAC ; cardiac functional
echocardiography ; LV ; end-diastolic volume ; mdp ; mitral valve opening ; mva ; pressure gradient
pd ; diuretic refractory ; hf ; prelated complications
ATP production rates ; mitochondrial oxidation ; fatty acids ; myocardial glycolysis
eplerenone ; potassium ; potassium ; hyperkalemia ; medication
New York Heart association ; heart failure ; hz ; ventricular ejection ; permanent periodic breathing ; pb ; report
implantation ; bottleneck stent ;LAD ;LCx ; reversible myocardial ischemia ; open stent ; ischemic heart failure ; stent
spironolactone ; aas
obese ; body mass index ; hff
proangiogenic effects ; VEg pathway ; injected ; adenoviral vector ; VEg receptor ; adenovirus ; treatment
surgery ; post- lVAD ; aortic valve ; leaflet repair ; bioprosthetic ; aortic valve replacement ; functional capacity ;cf lVAD ; AI
pulmonary artery systolic pressure ; pasp ; doppler echocardiography ; right ventricular contractile reserve ; pulmonary hypertension ; right heart failure
medline ;EMBAse ; healthstar ; cim ; cochrane Library ; Campbell Collaboration ; Joanna Briggs institute of evidence based practice ; evidence based practice
health care systems ; systolic heart failure ; prescribed ; angiotensin converting enzyme inhibitor ; angiotensin-receptor blocker
heart failure ; neuro-hormonal system ; angiotensin converting enzyme inhibitors ;angiotensin receptor blockers ; angiotensin converting enzyme inhibitors ; beta receptor blockers ; mineralocorticoid receptor antagonists
open chest model ; twist ; RS ; RS synchrony ; ste ;rvpo ; RS synchrony ; BiVP
tpse ; pasp ; tpse-to-PASp ratio ; truse ; cox regression ; kaplan-meier analyses
cPET ; CHF ; exercise ; exercise
heart failure ; hz ; mRNA ; voltage-gated cardiac ; scn5a ; endoplasmic reticulum
paediatric heart failure ; myocarditis ; dilated cardiomyopathy ; heart failure ; heart failure ; anthracycline ; malignant disease
economic ; Heart Failure ; costs
natriuretic peptides ;NPs ; acute heart failure ; Emergency department ; ed ; acute dyspnea
peak oxygen consumption ; peak VO2 ; vco2 slope ; exercise ; exercise oscillatory ventilation ; eOV ; end-tidal co2 ;PETco2 ; cardiopulmonary exercise testing
denmark ; bisphosphonates ; raloxifene
hypertension ; LV ; ms ; mitral valve ; organic lesion ; systolic ; diastolic tethering ; functional etiology ; ms
tolvaptan ; hyponatremia ; united states ; japon ; heart failure ; diuretic therapy ; sodium levels ; systolic function
longitudinal strain ; left ventricle ; echocardiographic ; baseline ; echocardiography ; ct ; follow-up echocardiograms
platelet-activating factor ; pf ; metabolic enzymes ; heart failure
acute care surgery ; acs ; ot ; transplantation ; medical therapy ; mt ; intravenous inotropes ; ventricular assist devices ;VADs
hfpEF ; ivabradine ; exercise capacity ; left ventricular ; filling pressure response ; exercise ; diastolic mitral flow velocity ; diastolic mitral annular velocity
renin-angiotensin-aldosterone system ; raas ; hf ; angiotensin-converting enzyme inhibitors ; angiotensin receptor blockers ; aldosterone blockade ; evidence ; hfpEF
admission ; lVET ; tonometric indices
heart rate ; blood pressure ; renal function ; spironolactone ; significant ;RAS ; blockers
cardiac ; β-adrenoceptor blockade ; heart failure ; SR ca(2+)-pump function ; reverse cardiac remodeling ; plasma catecholamines
angiotensin-converting enzyme inhibitors ;angiotensin receptor blockers ; β-blockers
SS31 ; congestive heart failure phenotypes ; mitochondrial damage induced ;TAC ; mitochondrial proteome ; mitochondrial ; nonmitochondrial protein changes
myofibrillar ; ATPase ; activity ; mRNA ; pump ; phospholamban ; mRNA ; metoprolol
HDl ;HDl ; CHF-NYha-III ;HDl
anesthetized dogs ; coronary microembolization-induced HF ; cXL-1020 ; left ventricular end-diastolic pressure ; myocardial oxygen consumption ; ejection fraction ; ventricular power index
mdc ; mdc ; mdc
baseline ; heart failure ; administration ; ms ; administration
etiologies ; hz ; la ; cardiomyopathy ; ischemic ; valvular ; alcohol
ST2 levels ; functional capacity ;HF ; Heart Failure ; exercise training ; hz
report ; cardiopulmonary exercise testing ; exercise rehabilitation ; heart failure ; exercise rehabilitation ; chronic heart failure ; chf ; Cardiopulmonary exercise testing ; cvp ; exercise rehabilitation ; china
aa ; ischemic HF pathogenesis ; NYha ; functional ; glomerular filtration rate ; heart rate ; hypertension ; diabetes mellitus ; myocardial infarction
hz-action ; exercise training ; hz ; left ventricular ejection fractions ; HRQol ; Kansas City Cardiomyopathy Questionnaire ; kv ; baseline
ct ; systolic dysfunction ; resynchronization reverses remodeling ; systolic left v entricular dysfunction ; left ventricular ;LV ; ejection fraction ;LVf
glomerular filtration rate ; egf ; diabetes ; cholesterol ; lDL-cholesterol ; ccnka GG
echocardiography ; end-diastolic dimension ; LV ; end-diastolic pressure ;wall stress ; lung weight ; aCF

spironolactone ; death
cardiac ; driven ; costs ; antiarrhythmic drugs
diabetes mellitus ; cardiomyopathy ; β-blocker ; angiotensin-converting enzyme inhibitor ; angiotensin II receptor blocker
eplerenone ; post myocardial infarction ; Heart failure Efficacy ; survival study ; eweSUS ; post-myocardial infarction ; heart failure ; mortality ; aldosterone antagonist eplerenone
carvedilol ; metoprolol ; implantable ; cardioverter-defibrillator therapy ; MAD-crt ; multicenter Automatic Defibrillator implantation ; Cardiac resynchronization Therapy
heart failure-related mortality ; death
DASh ; srd ; brachial systolic pressure ; central end-systolic pressure
hf ; obese ; body mass index ; black ethnicity ; cardiomyopathy
mortality ;HF ; LVf ; Heart Failure survey ; israel
left ventricular ejection fraction ; world health organization ; idiopathic dilated cardiomyopathy ; coronary angiography
european society of Cardiology ; hff ; heart failure ; ejection ; left ventricle ; diastolic dysfunction ;impaired LV ; diastolic stiffness ; LV
myocyte ; cAMP production ; report ; receptors ; regulatory ; g-protein-coupled receptor kinase-2
pf-cp ; PAf ; lyso-paf-at ; PAf-AH ; lp-PLA2
heart failure ; ejection fraction ; cardiac rehabilitation ; nordic walking ; exercise
ds-stratified hazard ratios ; sitagliptin ; pioglitazone ; sitagliptin ; sulfonylureas ; sitagliptin ; insulin
skeletal muscle mass ; sarcopenic range ; muscle ; wasting ; significant ; wasting
exercise ; testosterone ; baseline ; peak oxygen uptake ; Beck depression inventory ; leg strength ; medical ; exercise
mortality ; hf ; readmissions ; hf ;hazard ratio
Heart Failure ; exercise training ; hz-action ; exercise ; psss ; exercise ; btes
ST2 ; mortality ; cardiovascular death ; hz ; mortality ; hazard ratios
New York Heart association ; cardiopulmonary ; exercise ; lean mass ; x-ray absorptiometry ; dXA ; calf muscle ; magnetic resonance spectroscopy
placebo ; dopamine ; nesiritide ; diuretic therapy ; renal function ; heart failure ; renal dysfunction
ct ; New York Heart association ; heart failure ; left ventricular ejection fraction ; QRs ; echocardiographic evidence ; left ventricular dyssynchrony
left ventricular ;LV ; ejection fraction ;HF ; right-sided cardiac catheterization ; transthoracic echocardiography ; transmitral flow velocities ; mitral annulus velocities ; diastole
acute coronary syndromes ; CAD ; bnp ; NT-probNP ; CAD
baseline ; hz ; activities ; lyso-paf-at ; PAf-cpt ; PAf ; pf-AH ; lp-PLA2
medical ; sternotomy ; aortic valve ; bioprosthetic valve replacement ; dacron patch closure ; aortic valve ; transcatheter ; aortic valve ; open surgery ; aortic valve replacement
cutoff value ; natriuretic peptide ; natriuretic peptide ; acute heart failure ; hz ; emergency department ; ed
cardiac troponin t ; ctnt ; high-sensitivity assay ; natriuretic peptide ; biomarkers ; hz ; hz ; Atherosclerosis risk ; communities ; ac
body mass index ; fat mass ; fat-free mass index
interquartile range ; body mass index ; interquartile range ; COPd ; CHF ; cf
reverse remodeling ; ejection fraction ; mortality ; hz ; dialysis
LV ; contractility ; LVf ; ratio of systolic blood pressure ; end-systolic volume
echocardiography ; LV ; end-diastolic volume index ; LV ; ejection fraction ; MR ; mitral valve opening ; ms ; mva ; pressure gradient
rey ; heart failure ; renal dysfunction ; glomerular filtration rate
molecular analysis ; bets ; chromatin-mediated signal transduction ; transcription factor networks ; hz ; nuclear factor ; activated t cells ; naFAT ; nuclear factor ; transcription factor ;ATA4
guideline ; mortality ; exercise ; cardiovascular events ; myocardial infarction ; heart failure ; arrhythmia ; cardiac death ; hypertension ; venous thromboembolic events ; ischemic cerebrovascular events
cardiovascular mortality
edoc-cfus ; diabetes ; diabetes ; ee-cfu ; peak VO2 ; diabetes ; ee-cFUs ; peak VO2
immunoblotting ; fluorescence resonance energy transfer-based assays ; video edge detection ; epifluorescence microscopy ; ca2 ; myocardial tissues ; cardiomyocytes ; hz
east ; atrial fibrillation ; stroke prevention trial ; onset ; af ; stroke ; cha2s2VASc ; care ; rhythm control ; outcome assessment trial
exercise capacity ; peak oxygen consumption ;VO2 ; qol ; Minnesota Living with Heart Failure ; mlf ; questionnaire ; heart failure
TAC-induced proteomic ; mitochondrial-targeted peptide ; SS31 ; mitochondrial function ; upstream signal ;TAC ; mitochondrial-targeted peptide ; heart failure
left ventricular ejection fraction ;HF ; left ventricular ejection fraction ; admitted ; hospital ; medical ; financial ; costs
hf ; left ventricular ;LV ; ejection fraction ; hfpEF ; echo-doppler studies ; pro-brain-type natriuretic peptide assessment
eds ; hospitalized ; odds ratio ; EDs
cardiac transplant ; ect ; diabetes mellitus ; chronic kidney disease ; glomerular filtration rate
hbc Battery ; health ; hz ; risk model ; hz
cfi ; RMsea ; self-care maintenance Scale ; cfi ; RMsea ; self-care management Scale ; cfi ; RMsea ; self-care Confidence
BAT ; quality-of-life ; NYha ; change
hypoalbuminemia ; albumin levels ; hypoalbuminemia ; albumin levels ; lVAD
rehospitalization ; acute myocardial infarction ;AMI ; complications ; kidney infection ; urinary tract infection ;UTI
heart failure ;HF ; cardiomyopathies ; pharmacological ; implantable ; cardioverter defibrillators ; cardiac resynchronization therapy ; cardiac transplantation ; ventricular assist
SAF ; pf ; catheterization ; central venous pressure ; hg ; svr ; cardiac index
admission ; bnp ; bnp ; borderline
heart failure ; admission ; heart transplantation ; death ; death
ejection fraction ; velocity ; systolic elastance ; contractile efficiency ; aCF ; aCF ; allopurinol rats ; o2 consumption rate ; cardiomyocytes ; extracellular flux analyzer
hfpEF ; LV ; hypertrophy ; relative wall thickness ; rwt ; rvh ; rwt
lCZ696 ; angiotensin receptor ; neprilysin inhibitor ; neprilysin inhibitor prodrug ; angiotensin receptor antagonist valsartan ; hypertension ; heart failure ; ejection fraction ; outcomes ; heart failure ; ejection fraction
blood pressure ; mitral valve plasty ; MR ; chordal ruptures ; edge-to-edge anastomosis ; ring annuloplasty ; Physio ring 30 ; edwards lifesciences ; irvine
shuttle walk test ; peak oxygen uptake ; muscular strength ; echocardiographic ; natriuretic peptide ; inflammatory markers ; depression ; beck depression inventory ; minnesota ; Heart Failure Questionnaire ; medical
term ; LVEF ; mortality ; LVEF
westar-kyoto ; lean ; zSF1 ; obese ; zSF1 ; high-fat diet ; metabolic ; renal ; echocardiographic ; hemodynamically ; euthanization
kaplan-meier curves ; log-rank testing ; UM ; va-t
multivariate cox regression ; af ; af ; hypertension ; sinus rhythm ;hazard ratio
chronic HF-ref ; NYha ; functional class II ; egf ; potassium ; eplerenone ; hyperkalemia ; wf
body composition ; fm ; fm ; body fat distribution ; dual energy x-ray absorptiometry ; dXA ; non-diabetic patients ; chronic heart failure ; chf ;cc ; CHF ; myocardial infarction-both
baseline ; spironolactone ; end point of death ; hz ;hazard ratio ; AAs ;hazard ratio
pulmonary arterial hypertension ; chronic thromboembolic pulmonary hypertension ; right ventricular pump function ; pulmonary arterial hypertension ; medication ; stress echocardiography ; cardiopulmonary exercise testing
cardiovascular death ; hz ; btes ; btes ; cardiovascular death ; hz ; exercise ;hazard ratio
index ed ; ed ; death ; readmission ; aor ; eds ; aor
implantable cardioverter-defibrillator deactivation ; implantation ; decisions ; implantable cardioverter-defibrillator deactivation
Cardiac magnetic resonance ; atrial area ; pulmonary vascular resistance ;hazard ratio ; cardiac events
hf ; systolic ; ventricular ejection fraction ;HF ; conditions ; New York Heart association ; echocardiographic ; cardiopulmonary ; exercise
heart failure ; abd ; american college of Cardiology ; acc ; american Heart association ; haa ; New York Heart association ; nyha ; structural heart disease ; heart failure ; medical
mva ; mitral filling flow ; mva ; velocity time ; mitral filling flow ; wave doppler echocardiography ; mitral valve plasty
statitistical significance ; mortality ; sts ; hz ; cre ; Cr
hzPSI ; ann arbor ; veterans ; affairs ; hz ; va ; hzPSI ; va-RT ; va ; hzp
aas ; spironolactone dose ; hyperkalemia ; hypokalemia
LVEF ; mortality ; LVEF ;hazard ratio ; LVEF ; LVEF
hfpEF ; primary outcome ;odds ratio ; nyha ; walk test ; mwt ; prescribed
pulmonary arterial systolic pressure ;PASp ; right ventricular ;rv ; tricuspid annular plane systolic excursion ;TAPSe ; diastole ; end-systole ; heart failure ;HF ; cardiac risk
CAD ; diabetes ;odds ratio ; electrocardiographic ;odds ratio ; nondiabetes ; dyslipidemia ; hypertension ; tobacco ;odds ratio
receiver ; operating characteristic curve ; ac ; pcp
trastuzumab-treated ; coronary artery disease ; hypertension ; trastuzumab administration ; CHF
LVf ; ct ; ct ; LV ; end systolic volume index ; LV mass
tgf-β signaling ; tgf-β receptor ; smad ; epithelial ; mesenchymal transition markers ; pluripotency marker nanog
hf ; diuretics ; mwt ; NYha
surgery ; hz ; postoperative echocardiography ; LV ; end-diastolic volume index ; LV ; ejection fraction ; MR ; mitral valve opening ; mitral valve area ; mva ; pressure gradient
systolic heart failure ; ivabradine ; SHIft ; systolic Heart failure ; treatment ; inhibitor ivabradine trial ; ivabradine ; echocardiographic
Hazard ratios ;hazard ratio ; New York Heart association ; functional
renal function ; Chronic Kidney Disease Epidemiology ; glomerular filtration rate ; egf
paradigm-HF ; chronic heart failure ; systolic dysfunction ; lf ; functional ; nyha II-III ; bn ; cardiovascular death ; heart failure ; arni ; lz696 ; sacubiltril ; valsartan
LV ; reverse remodeling ; pre-ct ; LV ; end-diastolic dimension index ; longitudinal strain ; left ventricle ; left atrial area ; right ventricular ; end-diastolic area ; right atrial area ; right ventricular ; change
hyperkalemia ; African Americans ; New York Heart association ;NYha ; hz ; left ventricular dysfunction ; spironolactone ; Randomized aldactone evaluation study ;RALes
irs1 ; irs2 ; heart ; hyperinsulinemia ; myocardial insulin resistance ; cellular dysfunction ; irs1 ; irs2 ; heart-specific ; irs2 ; double-knockout
natriuretic peptide ; diagnose ; stable coronary artery disease ; b-type natriuretic peptide ; bnp ; ventricular cardiomyocytes ; ventricular wall stress ; myocardial ischemia
prescription ; angiotensin-converting enzyme inhibitors ;angiotensin receptor blockers ; interquartile range ; β-blockers ; interquartile range
Therapy ; ivabradine ; change ; diastolic mitral flow velocity ; diastolic mitral annular velocity ; exercise capacity ; ivabradine ; oxygen uptake
liberal transfusion protocols ; mortality rates ; i2 ; mortality rates ; acute coronary syndrome
readmission ; follow-up visits
hek ; embryonic kidney ; sphingosine-1-phosphate ; agonist ; isoproterenol ; β-adrenergic receptor agonist
baseline ; kansas City ; Cardiomyopathy Questionnaire ; Minnesota ; Heart Failure Questionnaire ; depressive ; beck depression inventory ; depression ; natriuretic peptide ; endothelial function ; flow-mediated dilatation ; ventricular diastolic function
cardiovascular events ; atrial fibrillation ; left ventricular ejection fraction ; diabetes mellitus ; peripheral vascular disease ; myocardial infarction ; heart failure ; stroke ; glomerular filtration rate ; kidney injury
diastolic function ; ea ; ventricular-arterial coupling
disease risk score ; dRS ; saxagliptin ; sitagliptin ; saxagliptin ; pioglitazone ; saxagliptin ; sulfonylureas ; saxagliptin ; insulin
revascularization ; coronary artery bypass ; surgery ; percutaneous coronary intervention ; systolic blood pressure ; baseline electrocardiogram
biomedical ; biomedical ; chm ; left ventricular ejection fraction ; left ventricular diastolic end diameter
open-label crossover ; masked outcome assessments ; stable heart failure ; ventricular ejection fraction ; grly ; haplotype ; β2-receptor ; carvedilol ; metoprolol
ed ; ed ; aor ; aor ; ED ; aor
health Buddy program ; mortality ;hazard ratio ; inpatient admissions ; baseline
multivariable-adjusted hazard ratios ; DASh ; diet score
report ; aRIC ; hz ; systolic blood pressure ; antihypertensive medication ; smoking ; diabetes ; body mass index ; coronary heart disease ; heart rate ; hz ; auc ; net reclassification improvement ; nri
eplerenone ; hyperkalemia ; renal function ; wr ; emPHASIS-HF ; heart failure ; ejection fraction ; hz-ref ; New York Heart association ;NYha ; glomerular filtration rate ; egf ; serum potassium
nesiritide ; urine volume ;nesiritide ; change ; cystatin ;nesiritide
nordic walking ; functional capacity ; mwt ; physical ; activity ; right grip strength ; depressive ; hospital anxiety ; depression Scale
hyperkalemia ; wf ; diabetes ; egf ; systolic blood pressure ; hyperkalemia ; wf ; primary outcome ; hz ; cardiovascular mortality
PAf ; biosynthetic enzymes ;lyso-paf acetyltransferase ; dithiothreitol ; dt ; choline ; 1-alkyl-2-acetyl-sn-glycerol cholinephosphotransferase ; catabolic isoenzymes ; pf-acetylhydrolase ; phospholipase a2 ; leukocytes
ivabradine ; baseline ; follow-up exercise capacity ; oxygen uptake ; early diastolic mitral flow velocity ; diastolic mitral annular velocity
CHF ;Odds ratio ; chest radiation ; hypertension ;NAD ; h-oxidase ;RAC2 ; hfe ; doxorubicin efflux transporter
baseline ; follow-up ; NYha ; change ; Duke ; activity status index ; Kansas City ; Cardiomyopathy Questionnaire ; walk
dopamine ; urine volume ;dopamine ; change ; cystatin c level ;dopamine
baseline ; glomerular filtration rate ; chronic obstructive pulmonary disease ; diabetes ; peripheral vascular disease ; left ventricular ejection fraction ; iCD shocks ; New York Heart association ; atrial fibrillation ; hz ; mortality
peak oxygen uptake ; hazard ratio ; ventilatory efficiency slope ; hemoglobin ; left ventricular ejection fraction ; renal function ; renal disease ; sodium
Kansas City ; Cardiomyopathy ; Minnesota ; Living with Heart Failure ; Beck ; depression inventory ; zung ; flow-mediated dilatation diameter ; fes ; natriuretic peptide ; wave ratio
